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Abstract
Adenosine triphosphate (ATP) sensitive potassium channels (K Atp) transduce 
changes in cellular metabolism into changes in membrane potential. Activation of 
Katp channels causes vascular smooth muscle to hyperpolarize. This leads to a 
relaxation of the pre-contracted muscle. Inhibition of Katp channels produces 
membrane depolarisation and reduces the ability of the vascular smooth muscle 
to hyperpolarize and thereby relax.
Katp channels are inwardly rectifying potassium channels (Kir), which are 
inhibited by ATP and stimulated by magnesium bound nucleotides. The KAtp 
channel is an octomeric combination of two different protein subunits. The pore is 
formed by four Kir6.2 subunits, each of which is associated with a regulatory 
sulphonylurea receptor (SUR) subunit. KAtp channels are found in a diverse 
range of tissue and are composed of different Kir and SUR subunits. In smooth 
muscle, Kir6.2 is the pore forming subunit and SUR2B is the associated 
regulatory subunit.
A structurally diverse group of agents called KAtp channel openers (K atpC O s ), 
have affinity for the SUR of Katp channels, causing a hyperpolarisation of the cell 
membrane and a decrease in excitability. KAtp channel openers have a host of 
potential therapeutic targets, which range from urinary incontinence to obesity.
The KatpC O s  used in this study can be placed into two categories. The KatpC O s 
typified by pinacidil are sensitive to L-arginine analogues whereas the KatpC O s 
typified by cromakalim are insensitive to L-arginine analogues. This sensitivity 
appears to be independent of nitric oxide synthase (NOS) action as the 
vasorelaxant and Rb efflux responses to pinacidil are insensitive to the NOS 
inhibitor L-N5-(1-iminoethyl) ornithine (L-NIO).
Pinacidil and cromakalim are believed to have a degree of commonality in how 
they interact with the KatpC O  binding site on SUR2B. Some parts of pinacidil 
though are believed to interact with the area of the KatpC O  binding site that 
recognises L-arginine analogues. In contrast, cromakalim is not believed to 
interact with this particular region of the KatpC O  binding site, which explains the 
insensitivity of cromakalim to L-NAME.
1 Introduction
Potassium channels are a diverse group of ion channels, which have a crucial 
role in the control of cell excitability. Cells in a resting state have an intracellular 
potassium ion (K+) concentration that is twenty five times higher than the external 
K+ concentration. When a potassium channel opens, an efflux of positive charge 
and an outward current results. The efflux of K+ is a mechanism to recover, 
maintain or enhance the resting membrane potential. The opening of K+ channels 
enables the membrane potential of the cell to move towards the equilibrium 
potential for potassium. The equilibrium potential for potassium can be defined as 
the membrane potential produced when the concentration of potassium ions 
across the membrane are in equilibrium.
1.1 Adenosine Triphosphate Sensitive Potassium Channels
Adenosine triphosphate (ATP) sensitive potassium channels (K a t p )  are inwardly 
rectifying potassium channels (Kir), which are inhibited by ATP and stimulated by 
magnesium bound nucleotides, such as MgATP, adenosine diphosphate 
(MgADP), guanosine triphosphate (MgGTP), guanosine diphosphate (MgGDP) 
and uridine diphosphate (MgUDP). Studies have shown that K a t p  channels are 
octomeric combinations of two distinct types of protein subunit. The pore is 
formed of four Kir6.1 or Kir6.2 subunits, each of which is associated with a 
regulatory sulphonylurea receptor (SUR) subunit. Kir6.1 and Kir6.2 have two 
transmembrane domains connected by a pore loop, and belong to the Kir 
superfamily (Figure 1) (Ashcroft and Gribble, 2000b; Clement et a/., 1997; Shyng 
and Nichols, 1997; Inagaki et al., 1995). Kir channels were first recognised in 
1949. At present, seven subfamilies of Kir exist and are designated as Kirl.O to 
Kir7.0 (Doupnik et al., 1995). Functional expression of the Kir family showed that 
members exhibit either strong or weak voltage dependent rectification. K a t p  
channels are weak rectifiers. Kir channels are essential in the control of resting 
membrane potential, coupling cellular metabolism to cellular excitability.
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Figure 1. The structure of a K a t p  channel. A shows the pore surrounded by 
four inwardly rectifying potassium channel (Kir) subunits and four 
sulphonylurea receptor (SUR) subunits from a vertical perspective. B shows a 
Kir subunit surrounded by a SUR subunit. In addition, two nucleotide binding 
domains (NBDs) are also visible.
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the second subunit is referred to as the SUR because the purification and the 
cloning of the founding member of this family was based on its affinity for the 
sulphonylurea, glibenclamide (Aguilar-Bryan et a/., 1995). SURs are members of 
the ATP-binding cassette (ABC) or transport ATPase superfamily. SURs have 
seventeen, highly hydrophobic, transmembrane domains (TMDs) that are 
arranged in three groups, two groups of six and one group of five TMDs. The 
SUR has two intracellular loops that contain consensus sequences, which are 
required for nucleotide binding and hydrolysis. These sequences are called the 
nucleotide binding domains (NBDs) (Tusnady et a/., 1997; Aguilar-Bryan et al., 
1995). Within each NBD is a conserved region of around 200 amino acids 
consisting of a Walker A motif, a Walker B motif and a conserved linker 
sequence. A conserved lysine residue in the Walker A motif is required for ATP 
hydrolysis and an aspartate residue in the Walker B motif is involved in 
coordinating the magnesium ion of the magnesium nucleotides. The Walker A 
and B motifs are separated by the ABC signature motif. The signature motif 
distinguishes ABC transporters from other nucleotide triphosphate binding 
proteins, such as kinases, which also contain the Walker sequences 
(Theodoulou, 2000).
Endoplasmic reticulum retention signals are masked during the assembly of the 
SUR/Kir complex, which results in only fully assembled channels being able to 
reach the plasma membrane. An -RKQ- (-Arginine, Lysine, Glutamine-) motif can 
function to keep incompletely assembled K At p  channels from reaching the cell 
membrane. Changing the motif to -AAA- (-Alanine, Alanine, Alanine-) allowed the 
surface expression of either the SUR or the Kir in the absence of their partner 
subunit. This shows that control is maintained over the assembly of K a t p  
channels (Zerangue et al., 1999).
1 .2  Types of SUR and K atp Channel Location
K a t p  channels in different tissues have a pre-dominance of certain combinations 
of Kir and SUR subunits. Two different genes encoding SUR1 and SUR2 have
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been identified and further diversity is created by alternative splicing of SUR2 
mRNA (Chutkow et al., 1996; Inagaki et al., 1996; Isomoto et al., 1996). SUR1 
and SUR2 have a 67% sequence homology. A splice site in SUR2, distal to the 
Walker A and B motifs in NBD2, alters the C-terminal 42 amino acids forming 
splice variants which are known as SUR2A and SUR2B. SUR2A and SUR2B 
have a 98% sequence homology. The 42 amino acid segment of SUR plays a 
critical role in the differential activation of K At p  channels by the potassium 
channel openers diazoxide, pinacidil, cromakalim and nicorandil (Matsuoka eta l., 
2000). Although Kir6.1 or Kir6.2 coassemble with different SUR isoforms to form 
heteromultimeric K At p  channels, it is not believed that Kir6.1 or Kir6.2 
heteromultimerise with each other (Seharaseyon et al., 2000).
1 .3  ATP Sensitive Potassium Channel Openers (K atpC O s )
The term "potassium channel openers" was introduced to describe a group of 
novel synthetic molecules, which were typified by cromakalim that act by 
stimulation of ion flux through K+ channels (Hamilton and Weston, 1989; 
Hamilton et al., 1986). Hamilton et al. (1986) reported that cromakalim evoked 
smooth muscle relaxant effects by the opening of K+ channels in cell 
membranes. KATp channel opening properties have now been demonstrated in a 
diverse range of synthetic chemical structures and endogenous substances.
The opening of KAtp channels by KAjp C O s  causes hyperpolarisation of the cell 
membrane and a pharmacological means of decreasing the excitability of cells. 
This is thought to have potential in the treatment of diseases such as 
hypertension, asthma, angina and urinary incontinence (Lawson, 1996). KAjpCOs 
such as pinacidil have shown that they can reduce elevated blood pressure in 
patients. The mechanism of this effect is an actively mediated decrease in 
peripheral resistance. The beneficial antihypertensive effects of pinacidil are also 
accompanied with the adverse effect of a weight gain in approximately 30% of 
patients (Carlsen etal., 1983).
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Classification of KatpC O s has been defined as a consequence of their ability to 
stimulate K+ flux through the Katp channel and their sensitivity to blockade by 
sulphonylureas. The sulphonylurea group of drugs was developed as a result of 
a chance observation that a sulphonamide derivative (used to treat typhoid) 
resulted in a marked lowering of blood glucose (Rang et al., 1999). The principal 
action of sulphonylureas is on the KAtp channels in (3 cells of the islets of 
Langerhans. The sulphonylureas reduce the potassium permeability of p cells by 
blocking Katp channels. This in turn causes membrane depolarisation, Ca2+ entry 
into the cell and insulin secretion. Sulphonylureas, such as glibenclamide and 
tolbutamide, have been used to treat non-insulin dependent diabetes mellitus 
(NIDDM) since 1955, but can stimulate appetite and cause weight gain (Rang et 
al., 1999, Gopalakrishnan etal., 1993, Ashcroft and Ashcroft, 1990).
Katp channel opening properties have been demonstrated in a diverse range of 
synthetic chemical structures (benzothiadiazines [e.g., diazoxide], pyrimidines 
[e.g., minoxidil], pyridylcyanoguanidines [e.g., pinacidil], nicotinamides [e.g., 
nicorandil], benzopyrans [e.g., cromakalim] and carbothiamides [e.g., RP 49356]) 
(Figure 2) (Edwards and Weston, 1990: 1993). Common chemical structural 
features between benzopyrans, pyridylcyanoguanidines and carbothiamides 
have been described. Atwal (1992) believed that there was a requirement for the 
KatpC O s  to have a hydrophobic group, an electron deficient aromatic ring and a 
hydrogen bonding site. This suggests that all KatpC O s  may interact with their 
site(s) of action in the same way as each other. An alternative pharmacophore 
model of the KatpC O s shows four common regions (Koga et al., 1993). Two of 
the regions represent areas of lipophilic interaction and the other two are 
hydrogen bonding regions.
In contrast to the suggestion that all KatpC O s  interact with the KAtp  channel in 
the same way, it is known that the KatpC O s  have heterogeneous pharmacologies 
For example, pinacidil, cromakalim and nicorandil open Katp channels in vascular 
smooth muscle and cardiac cells, but have no effect on pancreatic (3 cells.
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Figure 2. Structure of KatpCOs .
Diazoxide can open Katp channels in pancreatic (3 cells and vascular smooth 
muscle, but fails to open KAtp  channels in cardiac cells (Inagaki et al, 1995: 1996; 
Isomoto et al., 1996). This suggests that the pharmacology of the KAtp channels 
as characterised by the KAjpCOs is tissue dependent and indicative of multiple 
subtypes (Lawson, 2000).
1.4 Effect of Different Subunit Combinations
The specific properties of KAjp channels are determined by the SUR and Kir 
subunit composition (Figure 3),. The combination of subunits SUR1 and Kir6.2 
form the pancreatic (3 cell type of KAtp channel (Aguilar-Bryan et al., 1995). The 
combination controls insulin secretion by regulating the (3 cell membrane 
potential. SUR1/Kir6.2 is activated by diazoxide (E C 5o 20 - 100 pM), but is 
insensitive to pinacidil, nicorandil or cromakalim. SUR1/Kir6.2 is sensitive to both 
glibenclamide and ATP (IC50 around 1 nM and 10 pM respectively, Inagaki et al.,
1995). Mutations in either of the subunits causes loss of |3 cell KATP channel 
activity which causes the condition, familial hyperinsulinism, of which the most 
common form is Persistent Hyperinsulinaemic Hypoglycaemia of Infancy (PHHI) 
(Aynsley-Green et al., 2000). Cloning and expression of only SUR1, without the 
Kir subunit, demonstrated that SUR1 was sufficient to cause high affinity 
sulphonylurea binding, but not channel activity (Aguilar-Bryan etal., 1995).
In cardiac and skeletal muscle, the SUR2A/Kir6.2 complex forms the KAtp  
channel. The SUR2A/Kir6.2 combination has been shown to be insensitive to 
diazoxide, but is activated by pinacadil (EC50 65 pM), nicorandil (EC50 100 - 300 
pM) and cromakalim (EC50 30 - 100 pM). SUR2A/Kir6.2 is sensitive to both 
glibenclamide and ATP (IC50 6 nM and 100 pM respectively) (Inagaki etal., 1996; 
Findlay, 1992).
In vascular smooth muscle, the SUR2B/Kir6.2 complex forms the KAtp channel. 
The SUR2B/Kir6.2 combination is activated by pinacidil (EC50 0.6 pM), nicorandil 
(EC50 10 pM), cromakalim (EC50 2 pM) and diazoxide (EC50 37 pM).
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Figure 3. A summarised Ka tpC O  pharmacology of the sulphonylurea receptor 
(SUR) subtypes. Activation of the different SUR subtypes is indicated by D, P, 
C  and N for diazoxide, pinacidil, cromakalim and nicorandil, respectively. 
Percentage values represent the identity levels of the different SUR isoforms 
(Lawson, 2000).
SUR2B/Kir6.2 is sensitive to both glibenclamide and ATP ( IC 5o 100 nM and 53 
jjM respectively) (Wellman and Quayle, 1997; Inagaki etal., 1996; Isomoto et al.,
1996).
1.5 The K atpC O  Binding Site
KatpC O s  have been shown to interact with the SUR subunit of the Katp channel. 
For example, the pinacidil analogue [3H] P1075 can bind to cells that express 
SUR2B in the absence of Kir6.2 (Schwanstecher et al., 1998; Quast et al., 1993). 
In addition, Kir6.2 is not activated by KatpC O s when expressed in the absence of 
SUR but becomes activated when co-expressed with the SUR (John et al., 
1998).
Uhde et al. (1999) examined the diversity of the SUR subunits of Katp channels. 
By exchanging domains between SUR1 and SUR2B, and using [3H] P1075, two 
regions in the second set of transmembrane domains were identified as being 
crucial for KatpC O  binding. The regions identified as being crucial for KatpC O  
binding can be found in the intracellular loop connecting transmembrane 
domains 13 and 14 (Thr1059-Leu1087) and the domain preceding NBD2 
(Arg1218-Asn1320) (Figure 4). It is believed that these regions interact in the 
formation of the KatpC O  binding pocket. Nevertheless, as TMDs 1-13 are 
required for full KatpC O  affinity, additional regions may also be involved (Uhde et 
al., 1999).
Babenko et al. (2000) showed that two separate regions in SUR are necessary to 
determine the selective effects of diazoxide versus cromakalim or pinacidil. 
TMDs 6-11 and NBD1 of SUR1 were found to control responsiveness to 
diazoxide, whereas TMDs 12-17 of SUR2 confers sensitivity to cromakalim and 
pinacidil in chimeric human SUR1-SUR2A/Kir6.2 K atp channels. These results 
complement the study by D'Hahan et al. (1999), which showed that the transfer 
of TMDs 12-17 from rat SUR2A into hamster SUR1 is sufficient to allow the 
cromakalim analogue SR47063 to activate the chimeric SUR/Kir6.2 channels.
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NBD2
NBD1 COOH
1087
Figure 4. Putative transmembrane topologies of the regions essential for 
KatpCO (KCO I and II), nucleotide (NBD) and sulphonylurea binding (SUR). 
Adapted from Uhde etal., (1999).
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Babenko et al. (2000) also complements the observations made by Uhde et al.
(1999) that smaller segments, Thr1059-Leu1087 (KC01) and Arg1218-Asn1320 
(KC02) of rat SUR2 confer specific [3H] P1075 binding when placed in a hamster 
SUR1 background (Figure 4). The results suggest that the TMDs 12-17 are 
essential in forming a KatpC O  binding pocket. In addition, the Babenko et al.
(2000) study shows that stimulation by diazoxide involves domains of SUR1 
other than TMDs 12-17. The demonstration that stimulation by diazoxide involves 
domains of SUR1 other than TMDs 12-17 suggests that these domains either 
couple diazoxide binding at TMDs 12-17, or at another segment, to the Kir gating 
mechanism or form an additional KatpC O  binding site. Consistent with such a 
coupling mechanism, diazoxide can displace [3H] P1075 from SUR2B and [3H] 
glibenclamide from SUR1 (Schwanstecher et al., 1998). The results are 
compatible with a minimal model in which different classes of KatpC O s , including 
diazoxide, occupy the same site in TMDs 12-17 and that this site in SUR1 is in 
close proximity to the sulphonylurea binding site (SUR). The proximity of these 
sites suggests that negative allosteric interactions may be occurring. Therefore 
multiple regions of SUR contribute to coupling KatpC O  occupied sites with the Kir 
gating machinery. It is also suggested that KatpC O s  increase an ATPase activity 
of SUR and stabilise MgADP on NBD2 of SUR (Ueda et al., 1999). Therefore 
KatpC O  binding to TMD 12-17 and cooperative binding of ATP and MgADP to 
NBD1 and NBD2 respectively, may influence each other allosterically. This would 
explain the need for MgATP and intact NBDs for KatpC O  binding and the 
modulation of this binding by MgADP (Babenko et al., 2000; Hambrock et al., 
1999; Schwanstecher ef al., 1998).
Although 67% of the primary sequence of amino acids in SUR1 and SUR2A are 
identical, SUR1 and SUR2A possess around 300 non-matching amino acids 
throughout their sequences. The pancreatic isoform, SUR1 and the cardiac 
muscle isoform SUR2A along with the cromakalim analogue, SR47063 were 
used to establish which of the 300 non-matching amino acids between SUR1 and 
SUR2A are responsible for the observed differences in terms of potassium
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channel opener pharmacology (Moreau et aI., 2000). The KatpC O s , pinacidil, 
cromakalim and nicorandil act on SUR2 isoforms, but with the exception of 
diazoxide, the SUR1 isoform is insensitive to KatpC O s . Matched chimeras 
incorporating progressively smaller fragments of SUR2A in a SUR1 background 
led to the finding that the phenotype of SUR2A could be carried over to SUR1 
through single residue substitutions. The two SUR residues that were intimately 
involved in the activation of KAtp channels by KatpC O s were found to be located 
in the last TMD of SUR at positions 1249 and 1253 of SUR2A and at positions 
1286 and 1290 of SUR1. The residues are Leucine and Threonine in opener- 
sensitive isoforms SUR2A and SUR2B and Threonine and Methionine in SUR1. 
SUR1 mutants with the two residues from SUR2A acquired responsiveness to 
SR47063. The transfer of the two residues from SUR1 into SUR2A did not 
completely remove the responses to SR47063, which suggests that other regions 
of SUR2A are also important in cromakalim binding.
The two residues are believed to form part of the binding site for KatpC O s 
(Moreau et a/., 2000). The residues are one a helix turn away from each other 
and are therefore positioned adjacently on the same hydrophilic face of the last 
TMD17 (Moreau et al., 2000). Three other residues in TMD17 differ between 
SUR1 and SUR2A, but helical wheel projections predict these three residues lie 
on the opposite face of the helix. The transfer of these other three residues into 
SUR2A from SUR1 or from SUR1 into SUR2A failed to modify the KatpC O  
phenotypes of SUR1 or SUR2A. As SUR2B is identical to SUR2A, apart from 42 
amino acids at the C-terminal end (Isomoto et al., 1996), it seems likely that 
opener affinity is modulated by direct interactions between the C-terminal end 
and the neighbouring TMD17 (Moreau et al., 2 0 0 0 ).
The stoichiometry of KatpC O  action was examined by analysing the [3H] P1075 
sensitivity of channels coassembled from SUR1 and a chimeric construct derived 
from SUR1 and SUR2B, which had a high KCO affinity (Gross et al., 1999). Each 
Katp channel has four SURs for the binding of sulphonyiureas and KatpC O s
(Figure 1). When the action of [3H] P1075 is examined on the coassembled 
SUR1 and SUR2B channels, the occupation of one SUR subunit appears to be 
sufficient for channel activation. Concentration activation curves for 
complementary DNA (cDNA) ratios of 1:1 or 1:10 resembled those for channel 
opening resulting from interaction with a single site. Models for activation 
requiring the occupation of two, three or four sites did not correspond with the 
obtained data. Therefore, Katp channel activation appears to be mediated by the 
interaction of a single SUR subunit with a KatpC O  (Gross et al., 1999).
1.6 Function and Regulation of Katp Channels
The activity of Katp channels is affected by nucleotide levels, thus these channels 
link membrane conductance to metabolism (Cook & Hales, 1984). An example of 
the coupling of metabolism to electrical activity is pancreatic p cells. Under 
normal conditions, pancreatic p cell Katp channels stay open to maintain the 
membrane potential. When the blood glucose level increases, glucose is 
transported into the pancreatic p cell. The glucose is then metabolised, which 
increases the levels of ATP and decreases the concentration of MgADP in the 
pancreatic p cell. The increase in the ATP:ADP ratio closes the KAtp  channel, 
thereby depolarising the pancreatic p cell membrane. The depolarisation leads to 
the opening of Ca2+ channels, allowing Ca2+ influx into the p cells. The rise in the 
intracellular concentration of Ca2+ triggers insulin release (Misler etal., 1986).
In vascular smooth muscle, which is the basis of this project, the opening of Katp 
channels by a KatpC O , leads to an increase in the negativity of the resting 
membrane potential (hyperpolarisation) toward the equilibrium potential for 
potassium together with an outward current of K+ (Hamilton and Weston, 1989). 
This change in membrane potential is followed by a reduction in the levels of free 
intracellular Ca2+. The hyperpolarisation caused by the K+ efflux, closes the 
voltage activated Ca2+ channel, preventing Ca2+ from entering the cytosol, hence 
a reduction in the intracellular Ca2+ levels occur. At low calcium concentrations, 
very few of the calcium binding sites on troponin are occupied, and therefore
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cross bridge activity is blocked by tropomyosin. Following the application of the 
ai-adrenoceptor agonist, phenylephrine, there is a rapid increase in intracellular 
calcium levels, which allows calcium to bind to troponin, removing the blocking 
effect of tropomyosin, which allows cross-bridge cycling to occur. Other 
mechanisms may also contribute to the effects of KatpC O s . For example, in 
rabbit tracheal smooth muscle cells, cromakalim reduced the uptake into and the 
release of 45Ca2+ from the endoplasmic reticulum (Chopra et al., 1992).
1.7 The Effects of Magnesium Bound Nucleotides. ATP and ADP
The nucleotides ATP and ADP bind to an intracellular site on Kir6.2, and cause 
the K a t p  channel to close (Babenko et al., 1999). The photoaffinity analogue of 
ATP, 8 -azido-[y-32P]ATP, was shown to directly label COS-7 cells transiently 
expressing Kir6.2. This labelling was reduced by competition with ATP. The 
related subunit Kir4.1, which is not inhibited by ATP, is not labelled (Tanabe et 
al., 1999). Further evidence of the direct interaction of ATP with Kir6.2 is 
provided by the observation that mutations in Kir6.2 that reduce the inhibitory 
effect of ATP on channel activity also reduce the photoaffinity labelling (Tanabe 
etal., 1999).
To understand the roles of the two NBDs of SUR in the regulation of Katp 
channels, point mutations were introduced in the consensus sequence of the 
Walker A or B motif of each NBD of SUR1 and characterised ATP binding and 
ADP or MgADP antagonism to it (Ueda et al., 1997). SUR1 was photolabelled 
with 8 -azido-[a-32P]ATP and 8 -azido-[y-32P]ATP in the presence or absence of 
Mg2+. NBD1 mutations impaired ATP binding but NBD2 mutations did not impair 
ATP binding. MgADP antagonised ATP binding, and the NBD2 mutation reduced 
MgADP antagonism. These results show that SUR1 binds ATP at NBD1 even in 
the absence of Mg2+, and that MgADP, through binding at NBD2, antagonises 
the Mg2+ independent high affinity ATP binding at NBD1 (Gribble et al., 1997, 
Ueda et al., 1997).
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Ueda et al. (1999) has proposed a model of nucleotide activation of the Katp 
channel through the SUR1 subunit. Channel activation is induced when SUR1 
binds ATP in NBD1 and MgADP in NBD2. When the intracellular MgADP 
concentration decreases, MgADP dissociates from NBD2. MgADP dissociation 
from NBD2 leads to instability of ATP binding at NBD1, allowing the release of 
ATP. This dissociation of ATP from NBD1 may be involved in channel 
inactivation of the Katp channels. The model suggests that the intracellular 
concentration of MgADP is the primary factor determining the nucleotide 
activation of the KAtp channel.
The nucleotide binding properties of the NBD1 and NBD2 are different between 
SUR2A and SUR2B. The affinity of NBD1 of SUR2B for ATP is higher than that 
of SUR2A (Kj 51 and 110 pM respectively). The affinity of NBD2 of SUR2B for 
MgADP is higher than that of SUR2A (Kj 67 and 170 pM respectively) (Matsuo et 
al., 2000). As SUR2A and SUR2B share the same amino acid sequence except 
for their C-terminal 42 amino acids, this C-terminal region is thought to affect the 
nucleotide binding properties of NBD1 and NBD2 (Matsuo et al., 2000). Babenko 
et al. (1999) has reported that these C-terminal 42 amino acids specify the effect 
of ATP on gating. The C-terminal regions may therefore alter the sensitivity of the 
Katp channel to inhibitory ATP through affecting affinities of the NBDs of SUR2A 
and SUR2B to ATP (Matsuo etal., 1999: 2000).
For a potassium channel opener to bind to SUR2A and SUR2B, Mg2+ and ATP 
are required in the low micromolar range (EC50 3 -  5 pM respectively) 
(Hambrock et al., 1998: 1999; Schwanstecher et al., 1998). In addition, it has 
been shown that non-hydrolysable ATP analogues such as methylene-ADP or 
a,p-methylene-ATP do not support KatpC O  binding to SUR2B (Hambrock et al., 
1999; Schwanstecher et al., 1998; Dickinson et al., 1997). In the presence of 
MgATP, micromolar concentrations of MgADP formed by ATPase activity, 
increased [3H] P1075 binding to SUR2A, but inhibited [3H] P1075 binding to 
SUR2B. Hambrock et al., (1999) speculates that the carboxyl terminal of SUR2A
15
and SUR2B folds back to affect the interaction of MgADP with the [3H] P1075 
binding site. The carboxyl terminus may also form part of the binding site for 
KatpC O s  such as [3H] P1075 (Hambrock etal., 1999).
1 .8  Second Generation K atpC O s
KatpC O s  are recognised as having a therapeutic potential in the control of cell 
excitability (Lawson, 1996). Although attempts have been made to propose 
common pharmacophoric features for KatpC O s , the heterogeneous 
pharmacology due to the existence of SUR isoforms and the chemical diversity of 
the KatpC O s  suggests variation between the different KatpC O  binding sites. A 
disadvantage with the first generation KatpC O s is that they can cause significant 
side effects such as severe headaches and fluid retention (Atwal, 1994). A 
greater understanding of the KatpC O  pharmacophore for each SUR isoform will 
provide an insight into the KatpC O  binding sites. This knowledge should then 
lead to the production of rationally designed molecules, which offer highly 
selective modulation of distinct KatpC O  channel subtypes (Lawson and Dunne, 
2001, Atwal et al., 1993).
Development of second generation KatpC O s  through rational design and the 
identification of new chemical families with KatpC O  properties have provided 
agents with cardiac greater tissue selectivity (Atwal et al., 1993). Combining the 
structural features of cromakalim and pinacidil has led to the synthesis of 
compounds, which selectively exhibit either the vascular or cardiac properties of 
these agents (BMS-180448 -  cardiac selective and BMS-182264 -  vascular 
selective) (Figure 5, Atwal et al., 1993). This study not only allows the 
identification of tissue selectivity by uncoupling the smooth muscle relaxation 
from cardiac actions within the pharmacophore of KatpC O s , but also indicates 
that modifications of existing structures can provide the desired selective profiles 
required (Lawson, 2000).
16
Cromakalim
NCN
Cl- C
I
NH
NC OH
CH
CH3
NC
W //
H
N-
NCN
H
N-
CH3 c h 3
c -
H
C—  CH3 
CH,
BMS-180448 
Cardiac Selective
BMS-182264 
Vascular Selective
Nr
H
N-
NCN
H
N-
CH3 c h 3
c —  c —  c h 3
H |
CH,
Pinacidil
Figure 5. Tissue selective K a tp C O s . Compounds combining the structural features of 
cromakalim and pinacidil have allowed the separation of vascular smooth muscle 
relaxation from the cardiac actions of these K a tp C O s  (Atwal et al., 1993).
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New chemical groups of KatpC O s  such as the anilide tertiary compound, 
ZD6169, have been shown to display urinary bladder relaxant activity, but without 
hypotensive side effects (Howe etal., 1995).
In this project, second generation KatpC O s , which have been rationally designed 
from first generation KatpC O s , have been used. These compounds may enable a 
greater understanding of the KatpC O  pharmacophore and the KatpC O  binding 
site in vascular smooth muscle to be obtained.
A series of thienylcyanoguanidine derivatives, which possess different 
substituents on the thienyl ring have been studied. The thienylcyanoguanidine 
KatpC O s  have been evaluated for smooth muscle relaxation activity and are 
believed to bind to the KatpC O  binding site in the same way as pinacidil 
(Yoshiizumi et al., 1997, 2000). The way in which these thienylcyanoguanidine 
derivatives interact with KatpC O  binding site in rat isolated aorta will be examined 
by the use of L-arginine analogues. If the thienylcyanoguanidine derivatives 
interact with the KatpC O  binding site in the same way, then it would be 
reasonable to expect that the L-arginine analogues would be able to either 
modify all or none of the vasorelaxant responses to these KatpC O s .
1 .9  Effect of L-Arqinine Analogues on K atpC O  Induced 
Vasorelaxations
Vasodilatory responses to the KatpC O s  pinacidil and cromakalim have been 
shown to be attenuated by L-arginine analogues (Maczewski and Beresewicz, 
1997). In Langendorff perfused rat hearts, NG-nitro-L-arginine (L-NNA) reduced 
the basal coronary flow by 44% and NG-monomethyl-L-arginine (L-MMA) reduced 
the basal coronary flow by 43%. The pinacidil concentration response curve was 
displaced to the right by both L-MMA and L-NNA (Maczewski and Beresewicz, 
1997). In rat aorta derived from Sprague-Dawley rats, the vasorelaxant 
responses to the benzopyran KatpC O , BRL-38227 were selectively attenuated by 
the peptide endothelin-1 (ET-1) in contrast to the vasorelaxant responses to
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pinacidil and RP-49356 (thioformamide) that were insensitive to ET-1 Lawson et 
al., 1993). The nitric oxide synthase (NOS) inhibitory properties of the L-arginine 
analogues supported endothelium-derived nitric oxide (NO) playing a role in 
KatpC O  induced vasodilations (Janigro etal., 1997; Lawson etal., 1993).
In the endothelium, the L-arginine analogues, such as NG-nitro-L-arginine methyl 
ester (L-NAME), L-MMA or L-NNA (Figure 6 ), act by competing with L-arginine at 
the active site of NOS. NOS can catalyse the conversion of L-arginine to L- 
citrulline, and in the process produce NO (Anggard, 1994). If NO is produced by 
the endothelium, it diffuses to the vascular smooth muscle where it activates 
guanylate cyclase. The activation of guanylate cyclase, by a series of poorly 
defined events, then leads to a decrease in intracellular calcium and smooth 
muscle relaxation (Hamilton etal., 1999; Hobbs etal., 1999; Nichols etal., 1996).
L-NAME has also been suggested to inhibit KatpC O  vasodilation by directly 
blocking KAtp channels (Kontos and Wei, 1996). Studies to determine the 
mechanism by which L-arginine analogues modify the vasorelaxant effects of 
KatpC O s  have demonstrated that L-NAME can differentiate between structurally 
different KatpC O s  in the absence of a functional endothelium (Carr and Lawson, 
1999). This indicates that the endothelium and endothelial NOS are not involved 
in modifying the vasorelaxant responses to KatpC O s . These findings therefore 
suggest that KatpC O s do not possess a common pharmacophore and may 
interact with the KatpC O  binding site on the Katp channel in a different manner.
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Figure 6. The structures of the L-arginine (L-NAME, L-NNA and L-MMA) and 
the L-ornithine (L-NIO) analogues, which will be used in this project.
20
1.10 Aims of the Project
The aim of the project is to gain an insight into the KatpC O  pharmacophore and 
the KatpC O  binding site on the SUR2B. An improved understanding of both the 
KatpC O  pharmacophore and the KatpC O  binding site may allow the development 
of more specific molecules, which could offer selectivity to distinct KAtp channel 
subtypes to be produced. The chemical diversity of KatpC O s has suggested the 
involvement of multiple sites of action on the target membrane (Lawson, 1996).
KatpCO  pharmacophore and the KatpCO  binding site
L-NAME can selectively attenuate the vasorelaxant response to the 
cyanoguanidine KatpC O , pinacidil, in contrast to the benzopyran KatpC O , 
cromakalim in rat isolated aorta devoid of a functional endothelium (Carr and 
Lawson, 1999). To examine this difference in L-NAME sensitivity, a series of 
thienylcyanoguanidine KatpC O s , which are structurally similar to pinacidil, have 
been studied (Table 1) (Yoshiizumi et al., 1997). The thienylcyanoguanidine 
KatpC O s  are believed to interact with the KAtp channel in the same way as 
pinacidil (Yoshiizumi etal., 1997). The way in which these thienylcyanoguanidine 
derivatives interact with KatpC O  binding site in rat isolated aorta was examined 
by the use of the L-arginine analogues, L-NAME, L-MMA and L-NNA. If the 
thienylcyanoguanidine derivatives interact with the KatpC O  binding site in the 
same way, then it would be reasonable to expect that the L-arginine analogues 
would be able to either modify all or none of the vasorelaxant responses to these 
KatpC O s . If differences in the vasorelaxant responses to the 
thienylcyanoguanidine KatpC O s were observed, then this would provide clues as 
to how the thienylcyanoguanidine KatpC O s  interact with the KatpC O  binding site 
and an insight into the cyanoguanidine KatpC O  pharmacophore.
In contrast to pinacidil, L-NAME failed to modify the vasorelaxant responses to 
cromakalim. Other benzopyran KatpC O s  such as DY-9708, symakalim, 
bimakalim and SKP-450 were used to examine whether all benzopyran KatpC O s
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Table 1. A comparison of a series of 
thienylcyanoguanidine K a tp C O s  with pinacidil and KB- 
R10758. The skeleton structure is shown above the 
table. The substitutions to the structure are shown at 
positions R1f R2 and R3.
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interact with the KaTpC O  binding site on SUR2B in the same way. An insight into 
the benzopyran KaTpC O  pharmacophore should therefore be obtained.
Involvement of Nitric Oxide
The L-arginine analogues L-NAME, L-MMA and L-NNA inhibit nitric oxide 
synthase (NOS) activity. The effect of endothelium on the vasorelaxant 
responses to cyanoguanidine KaTpC O s in rat isolated aorta was examined in the 
presence of other NOS and guanylate cyclase inhibitors (L-N5-(1- 
iminoethyl)ornithine (L-NIO) and methylene blue respectively). This study was 
used to establish whether the sensitivity of the cyanoguanidine KaTpC O  induced 
vasorelaxations to L-arginine analogues such as L-NAME is due to the inhibition 
of NOS, or whether the L-arginine analogues are having an effect elsewhere in 
the vascular smooth muscle.
Mechanisms behind the responses
To examine the mechanism behind the modification of the vasorelaxant 
responses to pinacidil by L-NAME, a rubidium efflux assay was used. The 
rubidium efflux assay, studies the efflux of rubidium ions from the vascular 
smooth muscle as a direct consequence of KaTpC O  application. The rubidium 
efflux assay is used to trace the efflux of K+ and establish whether L-NAME is 
having its effect at the level of the KAtp channel or whether it may be affecting an 
alternative mechanism. A combination of these studies will provide valuable 
information into the functional cell biology of KAtp  channels in vascular smooth 
muscle.
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2 Methods
2.1 Vasorelaxation Studies on Pre-contracted Rat Aorta
The thoracic aorta was dissected from male Wistar rats weighing between 200 to 
250 g. The removed piece of aorta came from the section between the aortic 
arch and the diaphragm. Once dissected, the connective tissue was carefully 
removed from the aorta in Kreb’s bicarbonate solution (composition in mM: NaCI 
118.0, KCI 4.6, CaCI2 2.5, KH2P 0 4 1.0, MgS04.7H20  1.2, glucose 10.0 and 
NaHC0 3  25.0). Four equal rings, each measuring approximately 4 mm, were 
then cut from the thoracic aorta. The aortic rings were either denuded of 
functional endothelium by gently rubbing the intima using a pair of forceps, or the 
endothelium was left intact.
The aortic rings were individually suspended in organ baths (20 mis) containing 
Kreb’s bicarbonate solution maintained at 37 ± 1°C, and gassed with 95% 0 2 and 
5% C 0 2. An initial resting tension of 2 g was applied to the aortic rings. During an 
equilibration period of 80 - 100 minutes, the tension in the aortic rings was on 
occasion seen to either slightly contract or relax. When this occurred, the tension 
was adjusted back to the original 2 g of tension level after the bathing medium 
had been replaced with fresh Kreb’s bicarbonate solution at 20 minute intervals. 
The tension in the aortic rings was continuously recorded isometrically via FSG- 
01/20 force-displacement transducers (Linton Instrumentation) (Figure 7) and 
displayed on a Gould (8000) chart recorder.
When equilibrium had been reached, the aortic rings were maximally contracted 
by the addition of phenylephrine (1 pM) to the bathing medium. Once the 
contraction due to phenylephrine had reached a plateau, the integrity of the 
endothelium was determined by the subsequent addition of acetylcholine (1 pM). 
The failure of acetylcholine to produce a relaxation showed that the endothelium 
was non-functional. If functional endothelium was still present, then a relaxation
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occurred (Figure 8). Following the confirmation of the presence or absence of the 
functional endothelium, the bathing medium was replaced with fresh Krebs 
bicarbonate solution, until the tension in the preparations had returned to pre- 
contractile levels.
2.2 Experimental Protocol
Once the tension had returned to pre-contractile levels, a pre-treatment was 
applied to the aortic rings for 30 minutes. Table 2 shows the pre-treatments that 
were applied to the aortic rings in the study. The concentrations relate to the final 
concentration of the compound in the bathing medium.
Ten minutes after the addition of pre-treatment, the aortic rings were contracted 
with phenylephrine (1 pM). A 100% contraction is achieved when the aortic ring 
has been maximally contracted by phenylephrine (1 pM) and the contraction has 
reached a plateau during the 20 minute period prior to the application of the 
KaTpC O s . Thirty minutes after the addition of the pre-treatment to the bathing 
medium, cumulative concentrations of KatpC O s  were added to the baths. The 
range of final concentrations of the KatpC O s  in the bathing medium, are recorded 
in Table 3.
In the following experiments, only one concentration response curve (either 
control or test) was obtained per aortic ring preparation and only one ring 
preparation per animal was exposed to a particular treatment regime.
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Figure 8. The effect of phenylephrine and acetylcholine on aortic rings, with 
(A) and without (B) a functional endothelium.
27
Pre-Treatment Concentration of pre-treatment in 
bathing medium (pM)
L-arginine analogues
NG-nitro-L-arginine methyl ester 
(L-NAME)
30, 100 or 300
NG-monomethyl-L-arginine (L-MMA) 10, 30 or 100
NG-nitro-L-arginine (L-NNA) 10, 30 or 100
L-ornithine analogue
L-N5-(1-iminoethyl) ornithine (L-NIO) 100
Other
Methylene Blue 10
Table 2. The concentrations of pre-treatments used in the vasorelaxation study.
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KaTpC O Concentration range of KaTpC O  used 
(pM)
Pinacidil 0.05 - 25.6
Cromakalim 0.05 - 3.2
KB-R6844 0.05 - 25.6
KB-R6907 0.05 - 25.6
KB-R10101 0 .05 -12 .8
KB-R10757 0.05 - 25.6
KB-R10758 0.001 - 0.256
DY-9708 0.004 - 0.256
Bimakalim 0.004 - 0.256
Symakalim 0.004 - 0.256
SKP-450 0.0001 - 0.064
Table 3. The concentration ranges of the KaTpC O s  in the bathing medium used in 
the vasorelaxation studies. The cyanoguanidine KaTpC O s are in italics and the 
benzopyran KaTpC O s are in bold.
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In each study, the lowest concentration of KaTpC O  was initially added to the 
bathing medium. Once the relaxation produced as a consequence of adding the 
KaTpC O  had reached a plateau, the next concentration of KaTpC O  was added 
(Figure 9). The end of the concentration range was determined either when the 
addition of the proceeding concentration of KaTpC O  failed to produce further 
relaxation, hence the concentration response curve had reached a plateau or 
when 100% relaxation had been reached. A 100% relaxation is noted when the 
level of contraction in the isolated aortic rings has returned to baseline levels. 
The KaTpC O s were added hemilogarithmically, which means the concentration of 
KaTpC O  in the bathing medium doubled with each addition of KaTpC O . The only 
alteration to this procedure occurred in areas of the concentration response 
curve where a large relaxation (50%) was recorded with the doubling of the 
concentration of KatpC O . When this was noticed, additional, smaller increases in 
KatpC O s  were made in future experiments, to ensure that smaller relaxations 
were obtained.
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Figure 9. A trace of a typical concentration dependent relaxation to a K a tp C O  
in rat isolated aorta. The trace shows that a contraction occurs after the 
addition of phenylephrine (PE). Once the phenylephrine-induced contraction 
has reached a plateau, cumulative concentrations of a K a tp C O  are added to 
the bathing medium. The resulting relaxations are used to construct 
concentration-response curves to the K atp C O .
2.3 Introduction to Rubidium Efflux Assay
A non-radioactive rubidium efflux assay for functional analysis of ion channels 
has been used (Terstappen, 1999). The tissue is loaded with rubidium ions (Rb+), 
a tracer for potassium ions (K+), and after channel activation, Rb+ distribution 
between intracellular and extracellular space is determined by atomic emission 
spectroscopy. The relative amount of Rb+ in the supernatant is a direct measure 
of channel activity.
The advantages of this technique are that it is a safe and fast method for analysis 
of ion channels with conductivity for rubidium. As rubidium efflux is a direct 
measure of channel activity, the method is reliable and not prone to disturbances 
as is the case with indirect methods such as fluorescence-based procedures. 
The method also avoids the use of high-energetic radioisotopes like 86Rb, which 
represent severe hazards and need special safety precautions. In addition, such 
isotopes are expensive and their disposal is problematic.
The following study determines the effects of L-NAME and L-NIO on the pinacidil 
and cromakalim induced Rb efflux in rat isolated aorta. The data in the Rb efflux 
study is expressed in the form of the percentage Rb efflux in relation to the 
amount of Rb taken up by the aortic section devoid of endothelium during the 
incubation period. The control efflux is produced in the absence of pinacidil or 
cromakalim stimulation.
2.4 Rubidium Efflux Experimental Protocol
The rubidium efflux method used was modified from Terstappen (1999). The 
aorta was cut into 12 ring sections measuring 2 mm each. The 12 aortic sections 
were randomly placed into 12 individual wells on a 24 well plate. Each well 
contained 0.5 ml of Kreb’s bicarbonate solution (as described in section 2.1) 
containing RbCI (5.4 mM) in place of KCI. The Kreb’s bicarbonate solution 
containing RbCI, had a pH of 7.4 and was gassed for 30 minutes with 95% O2
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and 5% C 0 2 prior to being placed into the wells. The plate was placed in an 
incubator at 37 ± 1 °C for 4 hours. L-NAME (10-100 pM), L-NIO (100 pM), 
glibenclamide (1 or 10 pM), ouabain (10 mM) or vehicle (control) was added for 
the final 30 minutes of the 4 hour incubation. The concentrations of the above 
compounds represent the concentrations found in each individual well of the 
plate. At the end of the 4 hour incubation period, the plate was placed in a water 
bath at 37 ± 1 °C.
The individual wells containing the aortic section, firstly had the RbCI solution 
removed by pipette. The aortic ring section was then washed three times with 1.5 
ml of warmed Kreb’s bicarbonate solution (pH 7.4) containing KCI (4.6 mM) in 
place of RbCI and the relevant pre-treatment of L-NAME, L-NIO, glibenclamide or 
ouabain. Immediately after the last Kreb’s bicarbonate solution wash had been 
removed, 0.5 ml of Kreb’s bicarbonate solution (control) or 0.5 ml of Kreb’s 
bicarbonate solution containing either pinacidil (up to 50 pM) or cromakalim (up 
to 1.2 pM), and the relevant pre-treatment where required, was added to the 
aortic ring section for up to 8 minutes. The supernatant was then removed and 
added to 4.5 ml of distilled water in a bijou. The aortic ring section was then 
exposed to 0.5 ml of 10 % sodium dodecylsulphate (SDS) for 18 hours, after 
which, the lysate was removed and added to 4.5 ml of distilled water in a bijou.
The amount of rubidium present in the supernatant and lysate samples was 
determined by atomic emission spectroscopy at a wavelength of 780 nm. The 
atomic emission spectrometer was calibrated using a 2 pg/ml rubidium chloride 
standard. Once the wavelength of 780 nm had been set, the samples were 
sprayed into the acetylene flame of the spectrometer for analysis. The readings 
with the spectrometer offer a linear relationship with respect to rubidium 
concentration. Distilled water was introduced into the spectrometer between 
samples to ensure that each reading was entirely due to the rubidium that was 
present in the sample. If collected samples were not immediately analysed for
33
rubidium by atomic emission spectroscopy, then they were stored at 4°C without 
any negative effects on rubidium analysis (Terstappen, 1999).
2.5 Data Analysis
2.5.1 Vasorelaxation Studies on Pre-contracted Rat Aorta
Responses to the K atp C O s  after the respective treatments were compared with 
responses from time matched control preparations from the same animal. 
Concentration-response curves , were constructed with the data expressed as 
mean ± standard error of the mean (s.e.m.) of n determinations. The 
concentration-response curves are expressed as the log concentration of 
K atp C O  across the x axis and the % relaxation of the pre-contracted isolated rat 
aorta on the y axis. Differences between the paired data points, which formed the 
test and control concentration response curves, were evaluated by an unpaired t- 
test. When P was less than 0.05, the two values were considered to be 
statistically different. The Emax (maximum relaxation response (%) where 100% = 
return to pre-contraction baseline) and EC50 (concentration of compound required 
to relax the pre-contracted aorta by 50% in comparison with the control 
maximum) values were calculated for individual concentration-response curves. 
Mean ± s.e.m. values for Emax and EC50 were calculated from the individual 
values. Concentration ratios (CR) were initially calculated by comparing the EC50 
values from individual test and control curves.
CR = Test EC50 / Control EC50
Mean concentration ratios with 95% confidence limits (CR(cl)) were then 
determined from the individual concentration ratios.
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The n value relates to the number of different animals used in each experiment. 
Control Hill co-efficients were calculated using the GraphPad software (Prism 
3.0).
2.5.2 Rb Efflux Studies
The % Rb efflux in each test and control experiment, was calculated using the 
following formula.
% Efflux = Rb Content of Supernatant x 100
(Rb Content of Supernatant + Lysate)
The mean ± s.e.m. for n determinations (number of aortic sections per test or 
control group) were statistically evaluated by an unpaired t-test. When P was less 
than 0.05, the two means were considered to be statistically different.
2.6 Reagents
Potassium chloride (KCI), magnesium sulphate (MgSO4.7H20), sodium hydrogen 
carbonate (NaHC03), calcium chloride (CaCI2), rubidium chloride (RbCI) and 
potassium dihydrogen orthophosphate (KH2P 04) were supplied by BDH, Poole, 
UK. Ouabain, dimethyl sulphoxide (DMSO), pinacidil, NG-nitro-l-arginine methyl 
ester hydrochloride (L-NAME), L-phenylephrine hydrochloride, NG-monomethyl-l- 
arginine hydrochloride (L-MMA) and acetylcholine chloride were supplied by 
Sigma, St. Louis, USA. Sodium chloride (NaCI) was supplied by Prime 
Chemicals, Rotherham, UK. NG-nitro-l-arginine hydrochloride (L-NNA) and L-N5- 
(l-lminoethyl)-ornithine dihydrochloride (L-NIO) was supplied by Calbiochem- 
Novabiochem Corporation, San Diego, USA. Glibenclamide and cromakalim
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were supplied by Roche Bioscience, Palo Alto, USA. D(+)-glucose anhydrous 
was supplied by Prolabo, Fontenay, France. KB-R10101, KB-R6844, KB-R6907, 
KB-R10757 and KB-R10758 were kindly donated by Dr K Yoshiizumi of Kanebo 
Ltd, Osaka, Japan. DY-9708 was kindly donated by Daiichi Pharmaceutical 
Company, Tokyo, Japan. SKP-450 was kindly donated by the Korean Research 
Institute of Chemical Technology, Seoul, South Korea. Bimakalim, and 
symakalim were kindly donated by Merck KgaA, Darmstadt, Germany.
L-NAME, L-MMA, L-NNA, L-NIO and ouabain (10 mM) stock solutions were 
freshly made by being dissolved in Kreb’s bicarbonate solution when required. 
Bimakalim, cromakalim, DY-9708, KB-R10101, KB-R6844, KB-R6907, KB- 
R10757, KB-R10758, pinacidil, SKP-450, symakalim and glibenclamide were 
dissolved in dimethyl sulphoxide and stored as a stock solution of 10 mM at - 
20°C, before being diluted in Kreb’s bicarbonate solution when required.
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3 - 6  Results
In rat isolated aorta devoid of (lack of relaxant response to acetylcholine (1 
pM)) or with a functional endothelium, phenylephrine (1 pM) evoked a 
contraction (0.75 g -  1.6 g) that maintained a stable plateau for at least 120 
minutes in control preparations. All of the Ka TpC O s  used in this project 
produced concentration-related relaxations of phenylephrine contracted rat 
aorta.
3.1 Intra and Inter-rat Variability
To examine intra-rat variability, a piece of rat aorta from one animal was 
divided into four ring sections and randomly suspended into four organ baths. 
Pinacidil (0.1 -  25.6 pM) produced concentration related relaxations of the 
phenylephrine contracted aortic ring sections (Figure 10A). Figure 10A shows 
that the shapes of the four concentration response curves were similar. The 
mean EC50 value to pinacidil from the four sections was 0.60 ± 0.07 pM. The 
EC50 values to pinacidil show that there is minimal variation between pieces of 
rat isolated aorta from the same animal.
Pinacidil (0.1 - 25.6 pM) produced concentration related relaxations of 
phenylephrine contracted rat aorta. A mean concentration response curve to 
pinacidil was derived from seventeen individual concentration response 
curves to pinacidil from seventeen different rats (Figure 10B). The mean EC50 
value to pinacidil was 0.54 ± 0.06 pM. Once more, when comparisons are 
made between the same or different animals, the variability between the EC50 
values to pinacidil is low.
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3.2 Effect of L-NAME and L-NIO on the Vasorelaxant Responses
to the K aTpC O s  Pinacidil and Cromakalim
The effects of L-NAME on the vasorelaxant responses to the cyanoguanidine 
KaTpC O , pinacidil, and the benzopyran KaTpC O , cromakalim, were determined 
in contracted rat isolated aorta devoid of endothelium. Exposure of the 
endothelium denuded rat aorta preparations to L-NAME (30, 100 or 300 pM) 
did not modify the base-line tension. Pinacidil (0.1 - 25.6 pM) and cromakalim 
(0.05 - 3.2 pM) produced concentration related relaxations of phenylephrine 
contracted rat aorta (Pinacidil EC5o 0.43 ± 0.08 pM and Cromakalim EC50 0.15 
± 0.08 pM, Emax 100% and 84 ± 6%, n=7/group respectively; Figure 11). The 
presence of L-NAME (100 pM), significantly (P<0.05) displaced to the right of 
the control, the CRC to pinacidil (EC50 1.66 ± 0.14 pM, CR(cl) 5.05 (3.56- 
6.54), n=7), without modifying the maximal response. Likewise, L-NAME (300 
pM), significantly (P<0.05) displaced to the right of the control, the CRC to 
pinacidil (EC50 1.75 ± 0.08 pM, CR(cl) 5.24 (3.45-7.01), n=7), without 
modifying the maximal response. L-NAME (30 pM), however failed to modify 
the CRC to pinacidil (Control EC50 0.58 ±0 .10  pM, L-NAME 30 pM EC50 0.92 
± 0.21 pM, n=6; Figure 12). As the displacement of the CRC to pinacidil by L- 
NAME (300 pM) was not greater than that observed with L-NAME (100 pM), 
L-NAME (100 pM) was used in the rest of the study. In contrast, the 
vasorelaxant responses to cromakalim in rat isolated aortic rings were not 
modified by L-NAME (100 pM) (EC50 0.20 ± 0.07 pM, n=7).
Exposure of the endothelium denuded rat aorta preparations to L-NIO (100 
pM) did not modify the base-line tension. L-NIO (100 pM) failed to modify the 
CRC to pinacidil (Control EC50 0.50 ± 0 .1 0  pM, L-NIO 0.73 ± 0.23 pM, n=6; 
Figure 13).
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3.3 Effect of L-MMA and L-NNA on the Vasorelaxant Responses
to the Cvanoquanidine KaTpCO Pinacidil
Exposure of the rat isolated aorta devoid of endothelium to L-MMA (100 pM) 
or L-NNA (100 pM) did not modify the base-line tension. Pinacidil (0.1 - 25.6 
pM) produced a concentration related relaxation of phenylephrine contracted 
rat aorta (EC50 0.41 ± 0.08 pM, Emax 100 %, n=6, Control Hill co-efficient 1.14 
± 0.25; Figure 14). L-MMA (100 pM) and L-NNA (100 pM) significantly 
displaced (P<0.05) the CRC to pinacidil to the right of the control curve 
without modifying the maximal response (L-MMA EC50 0.79 ± 0 .1 3  pM, CR(cl) 
2.15 (1.03-3.26) and L-NNA EC50 0.63 ± 0.08 pM, CR(cl) 1.65 (1.15-2.15), 
n=6, respectively). In contrast,"lower concentrations of L-MMA (10 and 30 pM) 
failed to modify the CRC to pinacidil (Control EC50 0.49 ± 0.08 pM, L-MMA 10 
pM EC50O.4 3  ± 0.09 pM, L-MMA 30 pM EC500.42 ± 0.05 pM, n=4; Figure 15). 
In addition, L-NNA (10 and 30 pM) also failed to modify the CRC to pinacidil 
(Control EC50 0.30 ± 0.07 pM, L-NNA 10 pM 0.34 ± 0.06 pM, L-NNA 30 pM 
0.32 ± 0.08 pM, n=4; Figure 15).
L-MMA (100 pM) or L-NNA (100 pM) produced a significant displacement of 
the CRC to pinacidil. Lower concentrations of either L-MMA or L-NNA failed to 
modify the CRC to pinacidil. In view of these observations, L-MMA (100 pM) 
was used in the rest of the study.
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4 Pinacidil or Cromakalim Induced Rubidium (Rb)
Efflux
4.1 Effect of Pinacidil on Rb Efflux
Pinacidil (50 |jM) was used to induce a Rb efflux in rat aorta, devoid of 
endothelium, that had been divided into twelve sections. The application of 
pinacidil (50 pM) to the aortic sections increased the Rb efflux relative to the 
control for the first minute (Figure 16). For longer time periods, the pinacidil 
induced Rb efflux was lower than the efflux produced after one minute, but 
still higher than that seen in the control sections.
In view of this, a period of one minute was allowed to elapse between pinacidil 
application and supernatant removal in subsequent studies. Pinacidil 
concentrations of 1, 5 and 35 pM, significantly (P<0.05) increased the Rb 
efflux in relation to the control efflux (control 4.83 ± 0.38%, 1 pM 8.55 ± 
1.15%, 5 pM 7.10 ± 0.49% and 35 pM 8.48 ± 1.43%, n=8; Figure 17). 
Statistical analysis showed that Rb effluxes produced as a result of pinacidil 
stimulation were not significantly different from each other at any of the 
concentrations of pinacidil used.
An examination of time points less than a minute showed that there was no 
significant increase in the Rb efflux produced 45 seconds after exposure to 
pinacidil (1 pM) compared to the control Rb efflux. A significantly increased 
efflux (P<0.05) between the test and control efflux values was only observed 
when 60 seconds were allowed to elapse between pinacidil (1 pM) application 
and supernatant removal (control 7.15 ± 0.68%, pinacidil 45 seconds 9.34 ± 
1.26%, pinacidil 60 seconds 13.28 ± 1.60%, n=8; Figure 18).
Smaller pinacidil concentrations (less than 1 pM) could also produce a 
significantly increased Rb efflux relative to the control efflux after a 60 second 
exposure period. Pinacidil (0.8 pM) produced a significantly increased Rb
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efflux (P<0.05) in relation to the control efflux (control 8.48 ± 0.97%, 0.8 pM 
16.76 ± 2.56%, n=8; Figure 19). There was no significant difference between 
Rb efflux induced by pinacidil 0.4 and 0.6 pM and the control efflux.
Rat isolated aorta exposed to pinacidil (0.8 pM) for 60 seconds has been 
shown to produce a significantly increased Rb efflux relative to the control 
efflux. The subsequent studies therefore examine the effect of L-NAME, L- 
NIO, cromakalim and glibenclamide on the Rb efflux produced as a 
consequence of exposing rat isolated aorta to pinacidil (0.8 pM) for 60 
seconds.
4.2 Effect of L-NAME on Pinacidil Induced Rb Efflux
Pinacidil (0.8 pM) caused a statistically significant (P<0.05) increase in Rb 
efflux relative to the control efflux (control 7.46 ± 0.69%, pinacidil 0.8 pM 
10.95 ± 1.53%, n=16; Figure 20). L-NAME (100 pM) alone failed to modify the 
Rb efflux relative to the control (L-NAME 100 pM, 6.28 ± 0.69%). L-NAME 
(100 pM) and pinacidil (0.8 pM) produced a Rb efflux which was significantly 
lower (P<0.05) than the efflux induced by pinacidil alone (L-NAME and 
pinacidil 6.64 ± 0.69%).
As L-NAME (100 pM) alone failed to modify the Rb efflux relative to the 
control efflux, it was assumed that lower concentrations of L-NAME would 
also fail to modify the Rb efflux. The effect of a range of smaller L-NAME 
concentrations (10, 30, 50 and 75 pM) on the pinacidil induced Rb efflux 
showed that when rat isolated aorta was exposed to L-NAME (75 pM) and 
pinacidil (0.8 pM) for 60 seconds, a significantly lower (P<0.05) Rb efflux was 
recorded in relation to the pinacidil (0.8 pM) induced Rb efflux (L-NAME 75 
pM and pinacidil 0.8 pM 6.17 ± 0.27%). Lower concentrations of L-NAME 
failed to modify the Rb efflux from that induced by pinacidil alone. As 
observed previously, pinacidil (0.8 pM) significantly increased (P<0.05) the Rb 
efflux relative to the control (control 6.82 ± 0.69%, pinacidil 0.8 pM 11.45 ± 
1.60%, n=6; Figure 21).
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Figure 20. Effects of L-NAME on the Rb efflux responses to pinacidil in rat isolated aortic sections devoid of endothelium. The sections were exposed to L- 
NAME for the final 30 minutes of incubation in the Kreb’s bicarbonate solution containing RbCI. The symbols * and # indicate a significant difference (P<0.05) 
in Rb efflux in comparison with the control or pinacidil alone Rb efflux values respectively. The % efflux values ± s.e.m. are derived from the Rb content of the 
supernatant and lysate fractions (n=16/group).
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4.3 Effect of L-NIO on Pinacidil Induced Rb Efflux
In contrast to L-NAME, the pinacidil induced Rb efflux was not modified by L- 
NIO. Pinacidil (0.8 pM) significantly increased (P<0.05) the Rb efflux in 
relation to the control Rb efflux (control 6.04 ± 0.69%, pinacidil alone 9.69 ± 
1.14%, n=11; Figure 22). L-NIO (100 pM) alone, failed to modify the Rb efflux 
from the control Rb efflux (L-NIO alone 5.42 ± 0.66%). L-NIO (100 pM) and 
pinacidil (0.8 pM), failed to modify the Rb efflux from either the control or the 
pinacidil induced Rb efflux (L-NIO 100 pM and pinacidil 0.8 pM 7.58 ± 0.61%).
These studies have shown that L-NAME (75 and 100 pM) but not L-NIO (100 
pM) can significantly reduce (P<0.05) the pinacidil induced Rb efflux. Further 
studies could investigate the effect of larger L-NAME and L-NIO 
concentrations on the pinacidil induced Rb efflux.
4.4 Effect of Glibenclamide on Pinacidil Induced Rb Efflux
Pinacidil alone significantly increased (P<0.05) the Rb efflux relative to the 
control (control 3.56 ± 0.39%, pinacidil 0.8 pM 7.73 ± 1.02%, n=11; Figure 
23A). Glibenclamide (10 pM) significantly lowered (P<0.05) the pinacidil 
induced Rb efflux in relation to the efflux stimulated by pinacidil alone 
(glibenclamide 10 pM and pinacidil 0.8 pM 4.97 ± 0.40%). In contrast, 
glibenclamide (1 pM) failed to modify the pinacidil induced Rb efflux 
(glibenclamide 1 pM and pinacidil 0.8 pM 5.84 ± 0.83%). Glibenclamide (1 
and 10 pM) alone also did not modify the Rb efflux relative to the control 
(glibenclamide 1 pM 5.34 ± 0.91%, glibenclamide 10 pM 4.76 ± 0.35%).
4.5 Effect of Ouabain on Pinacidil Induced Rb Efflux
Although the pinacidil induced Rb efflux was higher than the control efflux, the 
effluxes were not significantly different (control 5.73 ± 1.03%, pinacidil 0.8 pM 
8.39 ± 1.67%, n=7; Figure 23B). Ouabain alone (10 mM) failed to modify the 
Rb efflux relative to the control efflux (8.00 ± 0.52%). Ouabain (10 mM) also 
failed to modify the pinacidil induced Rb efflux (Ouabain 10 mM and pinacidil 
0.8 pM 8.13 ± 0.91%). In summary, the pinacidil induced Rb efflux was shown 
to be modified by glibenclamide (10 pM) but not by ouabain.
54
P<0.05 Vs Control
O 
c
xnijjg %
55
* *  P<0.05 Vs control
#  P<0.05 Vs pinacidil
alone
Control Pinacidil 0.8 Glib 1 pM Glib 1 pM + Glib 10 pM Glib 10 pM 
pM Pinacidil 0.8 + Pinacidil
pM 0.8 pM
Treatments
Control Ouabain 10 mM Pinacidil 0.8 pM Ouabain 10 mM +
Pinacidil 0.8 pM
Treatments
F ig u re  23. Effects of glibenclamide (A ) and ouabain (B ) on the Rb efflux responses to 
pinacidil in rat isolated aortic sections devoid of endothelium. The sections were exposed to 
glibenclamide or ouabain for the final 30 minutes of incubation in the Kreb’s bicarbonate 
solution containing RbCI and for the duration of the experiment with pinacidil. The symbols * 
and # indicate a significant difference (P<0.05) in Rb efflux in comparison with the control and 
pinacidil alone efflux values respectively. The % efflux values ± s.e.m. are derived from the 
Rb content of the supernatant and lysate fractions (n=11 and 7/group) respectively.
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4.6 Effect of Cromakalim on Rb Efflux
Cromakalim (1.2 pM) significantly increased (P<0.05) the Rb efflux in relation 
to the control efflux (control 5.06 ± 0.94%, cromakalim 1.2 pM 10.37 ± 0.47%, 
n=8; Figure 24). Cromakalim (0.4 and 0.8 pM) failed to modify the Rb efflux 
relative to the control (0.4 pM 7.50 ± 0.89% and 0.8 pM 7.44 ± 1.37%). As 
cromakalim (1.2 pM) produced a significantly increased Rb efflux in 
comparison to the control Rb efflux, the following studies examined the effects 
of L-NAME, glibenclamide and ouabain on a cromakalim (1.2 pM) induced Rb 
efflux over a 60 second time period.
4.7 Effect of L-NAME on Cromakalim Induced Rb Efflux
Cromakalim (1.2 pM) alone produced a significantly larger (P<0.05) Rb efflux 
in comparison to the control efflux (control 6.01 ± 1.13%, cromakalim alone 
10.90 ± 2.43%, n=9; Figure 25). L-NAME alone, failed to modify the Rb efflux 
from the control efflux (L-NAME 5.49 ± 0.35%). In contrast to the pinacidil 
study, L-NAME failed to modify the cromakalim induced Rb efflux from the Rb 
efflux induced by the presence of cromakalim alone (L-NAME 100 pM and 
cromakalim 1.2 pM 10.94 ± 1.96%). The Rb efflux induced by cromakalim and 
L-NAME was significantly larger (P<0.05) than the control efflux. L-NAME is 
therefore able to modify the pinacidil but not the cromakalim induced Rb 
efflux.
4.8 The Effect of Glibenclamide on Cromakalim Induced Rb 
Efflux
The presence of cromakalim (1.2 pM) alone produced a significantly higher 
(P<0.05) Rb efflux in comparison with the control efflux (control 5.73 ± 0.45%, 
cromakalim 8.55 ± 1.42%, n=12; Figure 26A). Glibenclamide (1 pM) 
significantly reduced (P<0.05) the cromakalim induced Rb efflux 
(glibenclamide 1 pM and cromakalim 5.32 ± 0.79%). Glibenclamide (10 pM) 
failed to modify the cromakalim induced Rb efflux (glibenclamide 10 pM and 
cromakalim 5.85 ± 0.80%). Glibenclamide (1 and 10 pM) alone also failed to 
modify the Rb efflux in relation to the control efflux (glibenclamide 1 pM 5.38 ± 
0.74%, glibenclamide 10 pM 5.27 ± 0.48%).
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A
12
5=LU
*  P<0.05 Vs Control
#  P<0.05 Vs Cromakalim Alone
Control Crom 1.2 |jM Glib 1 pM Glib 1 pM + 
Crom 1.2 |jM
Glib 10 pM Glib 10 pM + 
Crom 1.2 pM
T re a tm e n ts
B
XJ3
t t
LU
Control Ouabain 10 mM Cromakalim 1.2 pM 
T  re a tm e n ts
Ouabain 10 mM + 
Cromakalim 1.2 pM
F ig u re  26. Effect of glibenclamide (1 and 10 |jM) (A ) and ouabain (B ) on the Rb efflux 
responses to cromakalim in rat isolated aortic sections devoid of endothelium. The sections 
were exposed to glibenclamide or ouabain for the final 30 minutes of incubation in the Kreb’s 
bicarbonate solution containing RbCI and for the duration of the experiment with cromakalim. 
The symbols * and # indicate a significant difference (P<0.05) in Rb efflux in comparison with 
the control or cromakalim alone Rb efflux values respectively. The % efflux values ± s.e.m. 
are derived from the Rb content of the supernatant and lysate fractions (n=12 and 7 /group) 
respectively.
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4.9 The Effect of Ouabain on Cromakalim Induced Rb Efflux
Although the cromakalim induced Rb efflux was higher than the control efflux, 
the effluxes were not significantly different (control 5.73 ± 1.03%, cromakalim 
8.23 ± 0.91%, n=7; Figure 26B). Ouabain (10 mM) alone failed to modify the 
Rb efflux from the control efflux (ouabain 8.00 ± 0.52%). Ouabain also failed 
to modify the cromakalim induced Rb efflux (ouabain and cromakalim 8.77 ± 
0.72%). In summary, the cromakalim induced Rb efflux was shown to be 
modified by glibenclamide (1 pM) but not by ouabain.
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5  Cvanoquanidine K a tp C O s
Pinacidil-induced vasorelaxations in rat isolated aorta have been shown to be 
sensitive to the L-arginine analogue, L-NAME (100 and 300 pM). In contrast, 
cromakalim-induced vasorelaxations have been shown to be insensitive to L- 
NAME (100 |jM). In contrast, the pinacidil-induced vasorelaxations are not 
modified by the L-ornithine analogue, L-NIO (100 pM). However, two other L- 
arginine analogues, L-MMA (100 pM) and L-NNA (100 pM), have been shown 
to modify the vasorelaxant responses to pinacidil. The sensitivity of other 
cyanoguanidine KaTpC O s  to L-arginine analogues is explored in this study.
5.1 Vasorelaxant Responses to Cvanoquanidine K aTpC O s
The exposure of endothelium denuded rat aortic preparations to L-MMA 
(100 pM), L-NIO (100 pM) or methylene blue (10 pM) did not modify the base 
line tension.
Name of KaTpC O Concentration Range (pM)
KB-R6844 0 .0 5 -2 5 .6
KB-R6907 0 .0 5 -2 5 .6
KB-R10757 0 .0 5 -2 5 .6
KB-R10101 0 .0 5 -1 2 .8
KB-R10758 0.001 -0 .2 5 6
Table 4. Concentration ranges of the cyanoguanidine K a tp C O s  required to 
produce a concentration related relaxation of phenylephrine contracted rat 
aorta, devoid of an endothelium.
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KB-R6844
L-MMA (100 |jM) significantly (P<0.05) displaced the CRC to KB-R6844 to the 
right of the control curve, without modifying the maximal response (Control 
EC50 0.66 ± 0.05 pM, L-MMA EC50 1.68 ± 0.29 pM, CR(cl) 2.67 (1.50-3.85), 
Emax 100 %, n=7, Hill co-efficient 1.93 ± 0.21) (Figure 27). In the presence of 
L-MMA (100 pM) a significantly (P<0.05) larger concentration of KB-R6844 
was required to produce the same degree of relaxation as seen in the control 
sections between KB-R6844 concentrations ranging from 0.2 to 3.2 pM. L- 
NIO (100 pM) failed to modify the CRC to KB-R6844 (Control EC50 1.13 ± 
0.16 pM, L-NIO EC50 1.35 ± 0.28 pM, n=5; Figure 27). Methylene blue (10 
pM) also failed to modify the CRC to KB-R6844 (Control EC50 1.20 ± 0.17, 
Methylene Blue EC50 1-24 ±0 .16  pM, n=4; Figure 27).
KB-R6907
L-MMA (100 pM) significantly (P<0.05) displaced the CRC to KB-R6907 to the 
right of the control curve, without modifying the maximal response (Control 
EC50 2.28 ± 0.08 pM, L-MMA EC50 7.48 ± 1.79 pM, CR(cl) 3.22 (1.66-4.77), 
Emax = 1 0 0  %, n=5, Control Hill co-efficient 1.35 ± 0.17; Figure 28). In the 
presence of L-MMA (100 pM), a significantly (P<0.05) larger concentration of 
KB-R6907 was required to produce the same degree of relaxation as seen in 
the control sections between KB-R6907 concentrations ranging from 0.4 to
12.8 pM. L-NIO (100 pM) failed to modify the CRC to KB-R6907 (Control EC50 
2.64 ± 0.35 pM, L-NIO EC50 4.82 ± 1.46 pM, n=5; Figure 28). Methylene blue 
(10 pM) also failed to modify the CRC to KB-R6907 (Control EC50 2.44 ± 0.59 
pM, methylene blue EC50 5.76 ± 1.78 pM, n=4; Figure 28).
KB-R10757
L-MMA (100 pM) significantly (P<0.05) displaced the CRC to KB-R10757 to 
the right of the control curve, without modifying the maximal response (Control
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EC50 1.07 ± 0.30 pM, L-MMA EC50 1-99 ± 0.35 jjM, CR(cl) 2 . 1 2  (1.32-2.93), 
Emax 100 %, n=5, Control Hill co-efficient 1.45 ± 0.20; Figure 29). In the 
presence of L-MMA (100 pM), a significantly (P<0.05) larger concentration of 
KB-R10757 was required to produce the same degree of relaxation as seen in 
the control sections between KB-R10757 concentrations ranging from 0.3 to 
1.6 pM. L-NIO (100 pM) failed to modify the CRC to KB-R10757 (Control EC50 
1.54 ± 0.36 pM, L-NIO EC50 2.08 ± 0.35 pM, n=5; Figure 29).
KB-R10101 and KB-R10758
In contrast to pinacidil, the relaxant responses to KB-R10101 were not 
modified by L-MMA ( 1 0 0  pM) (Control EC50 0.16 ± 0.03 pM, L-MMA EC50 0.19 
± 0.05 pM, Emax 100%, n=7; Figure 30). In addition, L-MMA (100 pM) also 
failed to modify the relaxant responses to KB-R10758 (Control EC50 0.0024 ± 
0.0003 pM, L-MMA EC50 0.0027 ± 0.0005 pM, Emax 100%, n=5, Control Hill 
co-efficient 2.42 ± 0.72; Figure 30)
L-MMA (100 pM) significantly modified (P<0.05) the CRCs to pinacidil, KB- 
R6844, KB-R6907 and KB-R10757. In contrast, L-MMA (100 pM) failed to 
modify the CRCs to KB-R10101 and KB-R10758. The NOS inhibitor, L-NIO 
(100 pM) was unable to modify the CRCs to pinacidil, KB-R6844, KB-R6907 
and KB-R10757. In addition, the guanylate cyclase inhibitor, methylene blue 
(10 pM) failed to modify the CRC to KB-R6844 and KB-R6907.
5 .2  Vasorelaxant Responses to Cvanoquanidine K aTpC O s  in Rat 
Isolated Aorta with a Functional Endothelium
In rat isolated aorta with a functional endothelium (relaxant response to 
acetylcholine (1 pM)), phenylephrine (1 pM) evoked a contraction (0.75 -  1.6 
g) that maintained a stable plateau for at least 1 2 0  minutes in control 
preparations.
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Exposure of rat aorta preparations with a functional endothelium to L-NAME 
(100 pM), L-MMA (100 pM), L-NNA (100 pM), L-NIO (100 pM) or methylene 
blue (10 pM) did not modify the base line tension.
Name of Ka TpC O Concentration Range (pM)
Pinacidil 0.1 -2 5 .6
KB-R6844 0 .0 5 -2 5 .6
KB-R6907 0 .0 5 -2 5 .6
KB-R10758 0.0005 -  0.256
Table 5. Concentration ranges of the cyanoguanidine KaTpC O s  required to 
produce a concentration related relaxation of phenylephrine contracted rat 
aorta with a functional endothelium
Pinacidil
L-NAME (100 pM) significantly displaced the CRC to pinacidil to the right of 
the control curve, without modifying the maximal response (Control EC50 0.32 
± 0.04 pM, L-NAME EC50 0.87 ± 0.25 pM, CR(cl) 2.69 (1.23-4.15), Emax 100 
%, n=5; Figure 31). L-MMA (100 pM) significantly displaced the CRC to 
pinacidil to the right of the control curve without modifying the maximal 
response (Control EC50 0.33 ± 0.05 pM, L-MMA 0.66 ± 0.11 pM, CR(cl) 2.10 
(1.25-2.95), Emax 100%, n=4; Figure 31). L-NNA (100 pM) significantly 
displaced the CRC to pinacidil to the right of the control curve without 
modifying the maximal response (Control EC50 0.32 ± 0.05 pM, L-NNA 0.89 ± 
0.20 pM, CR(cl) 3.03 (1.07-4.98), Emax 100%, n=4; Figure 31).
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KB-R6844
L-MMA (100 |jM) significantly (P<0.05) displaced the CRC to KB-R6844 
without modifying the maximal response (Control EC50 0.39 ± 0 . 1 0  pM, L- 
MMA EC50 1.82 ± 0.70 pM, CR(cl) 4.43 (2.50-6.36), Emax 100%, n=5; Figure 
32). L-NIO (100 pM) significantly (P<0.05) displaced the CRC to KB-R6844 
without modifying the maximal response (Control EC50 0.40 ±0 . 10  pM, L-NIO 
EC50 2.13 ± 0.43 pM, CR(cl) 8.46 (1.75-15.18), Emax 100 %, n=5; Figure 32). 
Methylene blue (10 pM) significantly (P<0.05) displaced the CRC to KB- 
R6844 without modifying the maximal response (Control EC50 0.35 ± 0.14 pM, 
methylene blue EC50 166  ± 0.49 pM, CR(cl) 6.26 (1.54-10.97), Emax 100 %, 
n=3; Figure 32).
KB-R6907
L-MMA (100 pM) significantly (P<0.05) displaced the CRC to KB-R6907 to the 
right of the control curve, without modifying the maximal response (Control 
0.80 ± 0.32 pM, L-MMA EC50 2.34 ± 0.33 pM, CR(cl) 3.56 (1.87-5.24), Emax 
100 %, n=5; Figure 33).
KB-R10758
KB-R10758 (0.0005 -  0.256 pM) produced a concentration related relaxation 
of phenylephrine contracted rat aorta. In contrast, L-MMA (100 pM) failed to 
modify the CRC to KB-R10758 (Control EC50 0.0020 ± 0.0003 pM, L-MMA 
EC50 0.0024 ± 0.0005, Emax 100 %, n=5; Figure 33).
L-MMA (100 pM) was able to significantly modify the vasorelaxant responses 
to pinacidil, KB-R6844 and KB-R6907 but not to KB-R10758 in rat isolated 
aorta with and without a functional endothelium. The differences between the 
vasorelaxant studies in rat isolated aorta with and without a functional 
endothelium, were found in relation to L-NIO and methylene blue. In rat
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isolated aorta devoid of a functional endothelium, L-NIO and methylene blue 
failed to modify the vasorelaxant responses to any of the cyanoguanidine 
KaTpC O s . In the presence of a functional endothelium, L-NIO and methylene 
blue modified the vasorelaxant responses to KB-R6844.
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6  Benzopyran K a tp C O s
Cromakalim-induced vasorelaxations in rat isolated aorta have been shown to 
be insensitive to the L-arginine analogue L-NAME. The sensitivity of the 
benzopyran KaTpC O s , DY-9708, SKP-450, bimakalim and symakalim (Figure 
34) to L-arginine analogues in contracted rat isolated aorta devoid of 
endothelium is explored in this study.
6.1 Vasorelaxant Responses to Benzopyran K atp C O s
The exposure of endothelium denuded rat aorta preparation to L-NAME (100 
or 300 pM), L-MMA (100 pM), L-NNA (100 pM) or L-NIO (100 pM) did not 
modify the base-line tension.
Name of KaTpC O Concentration Range
DY-9708 0.004 -  0.256 pM
SKP-450 0 . 1 - 6 4  nM
Bimakalim 0.004 -  0.256 pM
Symakalim 0.004 -  0.256 pM
Table 6. Concentration ranges of the benzopyran K a tp C O s  required to 
produce a concentration related relaxation of phenylephrine contracted rat 
aorta.
DY-9708 and SKP-450
L-NAME (100 pM) significantly (P<0.05) displaced the CRC to DY-9708 to the 
right of the control curve without modifying the maximal response (Control 
EC50 0.016 ± 0.002 pM, L-NAME EC50 0.026 ± 0.005 pM, CR(cl) 1.93 (1.36- 
2.51), Emax 74 ± 10 %, n=10, Control Hill co-efficient 2.88 ± 0.63; Figure 35). 
L-NAME (300 pM) significantly (P<0.05) displaced the CRC to DY-9708, but 
failed to increase the displacement produced by L-NAME (100 pM) EC50 
0.030 ± 0.006 pM, CR(cl) 2.60(1.13-4.08). In contrast to DY-9708, the
75
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Figure 34. Structures of the benzopyran KaTpCOs studied.
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relaxant responses to SKP-450 (Figure 35) in rat isolated aorta were not 
modified by L-NAME (100 pM) (Control EC50 4.1 ± 0.5 nM, L-NAME EC50 7.0 
± 2.9 nM > Emax 100%, n=6).
L-MMA (100 pM) significantly (P<0.05) displaced the CRC to DY-9708 to the 
right of the control curve without modifying the maximal response (Control 
EC50 0.016 ± 0.003 pM, L-MMA EC50 0.039 ± 0.007 pM, CR(cl) 2.48 (1.42- 
3.53), Emax 94 ± 5%, n=7; Figure 36). L-NNA (100 pM) significantly (P<0.05) 
displaced the CRC to DY-9708 to the right of the control curve without 
modifying the maximal response (Control EC50 0.016 ± 0.003 pM, L-NNA 
EC50 0.038 ± 0.011 pM, CR(cl) 1.56 (1.01-2.11), Emax 94 ± 5%, n=7, Figure 
36). In contrast, L-NIO (100 pM) failed to modify the CRC to DY-9708 (Control 
EC50 0.018 ± 0.004 pM, L-NIO EC50 0.022 ± 0.001, n=4, Figure 37).
Bimakalim and Symakalim
L-MMA (100 pM) significantly (P<0.05) displaced the CRC to bimakalim to the 
right of the control curve without modifying the maximal response (Control 
EC50 0.018 ± 0.003 pM, L-MMA EC50 0.026 ± 0.003 pM, CR(cl) 1.57 (1.09- 
2.05), Emax 100 %, n=6, Hill co-efficient 1.32 ± 0.42). In contrast, L-MMA (100 
pM) failed to modify the CRC to symakalim (Control EC50 0.012 ± 0.002 pM, 
L-MMA EC50 0.015 ± 0.004 pM, Emax 100 %, n=6, Hill co-efficient 2.96 ± 0.46; 
Figure 38).
L-MMA (100 pM) and L-NAME (100 pM) but not L-NIO (100 pM) were able to 
modify the vasorelaxant responses to DY-9708. L-MMA also modified the 
vasorelaxant responses to bimakalim but not to symakalim. In contrast, L- 
NAME was unable to modify the vasorelaxant responses to either cromakalim 
or SKP-450.
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7 Discussion
The KaTpC O s  used in this project can be separated into two groups that are 
typified by pinacidil and cromakalim. The vasorelaxant responses to the 
pinacidil group of KaTpC O s are sensitive to the L-arginine analogues whereas 
the vasorelaxant responses to the cromakalim group of Ka TpC O s  are 
insensitive to L-arginine analogues in rat isolated aorta devoid of a functional 
endothelium. By inference, it can be suggested that the KaTpC O s  that are 
sensitive to L-arginine analogues activate a mechanism that is different to that 
operated by the KaTpC O s that are insensitive to L-arginine analogues. The L- 
NAME mediated inhibition of the vasorelaxant response to pinacidil was 
surmountable. In addition, the pinacidil induced Rb efflux is sensitive to L- 
NAME, whereas L-NAME failed to modify the cromakalim induced Rb efflux. 
In contrast to L-NAME, the NOS inhibitor L-NIO failed to modify both the 
vasorelaxant and Rb efflux responses to pinacidil. The vasorelaxant 
responses to pinacidil were also shown to be sensitive to two other L-arginine 
analogues, L-MMA and L-NNA.
7.1 Proposed Mechanism to Explain the L-Arqinine Sensitivity 
of the Vasorelaxant and Rb Efflux Resposes to Pinacidil
A possible mechanism to explain the sensitivity of the pinacidil induced 
vasorelaxant and Rb efflux responses to the L-arginine analogues is shown in 
Figure 39. Figure 39 suggests that large parts of pinacidil and cromakalim 
interact with the Ka TpC O  binding site on SUR2B in a similar manner. The 
yellow area on the diagram shows this commonality in binding to the KaTpC O  
binding site. The study though has shown that there are differences in the 
sensitivity of the KaTpC O s  to the L-arginine analogues. For example, in the 
presence of an L-arginine analogue, a larger concentration of pinacidil is 
required to produce the same degree of relaxation as seen in the control 
sections. This difference in sensitivity is shown by the blue region in Figure 
39. The blue region is the area where some parts of pinacidil interact with the
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Region where both cromakalim and 
pinacidil interact with the KaTpC O  
binding site.
Region where only cromakalim 
interacts with the KaTpC O  binding site.
Region where pinacidil and L-arginine 
analogues interact with the KaTpC O  
binding site.
Figure 39. A diagrammatic representation of how pinacidil, cromakalim and the L- 
arginine analogues interact with the Ka TpC O  binding site on SUR2B. The model 
shows there is a degree of commonality in how pinacidil and cromakalim interact with 
the KaTpC O  binding site (yellow area) but certain parts of the KaTpC O  binding site are 
sensitive to both pinacidil and the L-arginine analogues (blue area).
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Ka TpC O  receptor on SUR2B. This area of the KaTpC O  binding site may also 
be the area where the L-arginine analogues interact with the Ka TpC O  binding 
site hence explaining why a larger concentration of pinacidil is required to 
produce the same degree of relaxation in the presence of the L-arginine 
analogues. The red area of the diagram shows the area where some parts of 
cromakalim interact with the KaTpC O  binding site. The L-arginine analogues 
may not interact with this particular area of the K aTpC O  binding site explaining 
why the amount of cromakalim required to produce a relaxation is the same in 
the presence or absence of the L-arginine analogues.
Support for the model that only some parts of the KaTpC O  binding site are 
sensitive to L-arginine analogues is found when the concentration of L-NAME 
is increased to 300 pM. When the L-NAME concentration was increased, the 
pinacidil concentration response curve failed to be further displaced from the 
pinacidil concentration response curve that was produced in the presence of 
L-NAME (100 pM). If pinacidil was entirely sensitive to L-NAME, then it would 
be expected that an increased displacement of the concentration response 
curve to pinacidil would have occurred. It therefore follows that there is an 
insensitive component involved in the pinacidil induced vasorelaxations. This 
can be explained by the yellow part of the diagram that shows the 
commonality of pinacidil and cromakalim in binding to the KaTpC O  binding site 
on SUR2B. The model proposed suggests that an interaction between 
pinacidil and the L-arginine analogues is occurring at only a small part of the 
Ka TpC O  binding site (blue region) hence explaining why there is an insensitive 
component to the pinacidil induced vasorelaxations.
In contrast to L-NAME, the pinacidil induced vasorelaxant and Rb efflux 
responses are insensitive to the L-ornithine analogue, L-NIO. Kontos and Wei, 
(1996) suggested that the L-arginine analogues interact with SUR2B, but no 
evidence can be found to suggest that L-NIO interacts with SUR2B. It is 
therefore proposed that L-NIO is not interacting in any way with the Ka TpC O  
binding site on SUR2B hence explaining why the vasorelaxant and Rb efflux 
responses are insensitive to L-NIO.
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There are two KaTpC O s  that are hard to fit into the two distinct groups 
characterised by pinacidil and cromakalim. These two KaTpC O s  are DY-9708 
and bimakalim. Both of these Ka TpC O s  are similar in structure to the 
benzopyran KaTpC O , cromakalim, but these two KaTpC O s  are sensitive to L- 
arginine analogues. DY-9708 and bimakalim therefore appear to bind to the 
KaTpC O  binding site in a different manner to cromakalim. A possible 
explanation for this sensitivity to the L-arginine analogues can be that when 
these KaTpC O s  interact with the KaTpC O  binding site on SUR2B, some part of 
their structure interacts with the region on the Ka TpC O  binding site that is 
sensitive to both pinacidil and L-arginine analogues. This would then explain 
why a larger concentration of these KaTpC O s  is required to produce the same 
amount of relaxation in the presence of L-arginine analogues. In contrast, KB- 
R10101 is insensitive to L-arginine analogues suggesting that when KB- 
R10101 interacts with the KaTpC O  binding site, no part of KB-R10101 
interacts with the part of the Ka TpC O  binding site that is sensitive to L-arginine 
analogues. To conclude, the Ka TpC O s  used in this study show a large amount 
of commonality in their interactions with the KaTpC O  binding site on SUR2B. 
Their sensitivity to the L-arginine analogues derives from a section of their 
structure interacting with the part of the Ka TpC O  binding site that is sensitive to 
the L-arginine analogues.
The L-arginine analogues, L-NNA and L-MMA have been shown to inhibit the 
cerebral arteriolar dilation from pinacidil in cats (Kontos and Wei, 1996). This 
effect was shown to be independent of NOS activity. The inhibitory effect of L- 
NNA and L-MMA was reversed by L-arginine suggesting that the effect of the 
L-arginine analogues on K aTp channels may involve competition with L- 
arginine. It is therefore suggested that the requirement for L-arginine may be 
due to the presence of an arginine binding site on the SUR, which may need 
to be occupied to allow the KaTp  channel to open (Kontos and Wei, 1996, 
1998). These studies support the proposed hypothesis that the binding of an 
L-arginine analogue to a site on SUR2B can influence how pinacidil interacts 
with the KaTpC O  binding site in rat isolated aorta devoid of endothelium.
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The proposed model suggests how the KaTpC O s  interact with the KaTpC O  
binding site on the KaTp  channel. The model though cannot predict whether 
any additional responses are taking place following Ka TpC O  application. Do 
the KaTpC O s  bind to another part of the cell as well as the KaTpC O  binding 
site? Is an additional component linked to nitric oxide action? These additional 
questions are beyond the scope of this thesis, but provide thought provoking 
ideas for future research.
In contrast to this study that was performed in rat aorta, studies performed in 
the mesenteric arterial bed pf Wistar rats showed that the concentration 
response curves to the KaTpC O s , levcromakalim and pinacidil were displaced 
to the left of the control curve in the presence of L-NAME. This suggests that 
basal nitric oxide has a modulatory effect on the interaction between KaTpC O s 
and KaTp  channels in this vascular bed (McCulloch & Randall, 1996). It is 
therefore possible that the L-arginine analogues have different effects on the 
vasorelaxant responses to KaTpC O s  depending on where in the body the 
KaTpC O s  are acting.
7 .2  K a tp C O  Binding Site
Several studies have elucidated the regions of the SUR, which are involved in 
the activation of K aTp channels by KaTpC O s  such as pinacidil and cromakalim 
(Babenko et al., 2000; Moreau et al.t 2000; Uhde et al., 1999 and 
Schwanstecher et al., 1998). Although the studies have determined the 
regions of the SUR, which confer the majority of the sensitivity to these 
KaTpC O s , they have commented that to obtain a complete KaTpC O  induced 
activation of the KaTp channel, additional regions of the SUR are required. 
This study has shown that the pinacidil induced vasorelaxant and Rb efflux 
responses are sensitive to L-NAME, whereas the cromakalim induced 
vasorelaxant and Rb efflux responses are insensitive to L-NAME. If additional 
SUR regions are required to produce a complete pinacidil or cromakalim 
induced activation of the KaTp  channel, then this suggests that the some 
aspects of the binding sites for pinacidil and cromakalim may be different and
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supports the previously discussed model explaining how pinacidil and 
cromakalim interact with the Ka TpC O  binding site on SUR2B.
7 .3  Common K aTpC O  Pharmacophore
Common features between cyanoguanidine and benzopyran Ka TpC O s  have 
been described and have led to the suggestion that there is a requirement for 
Ka TpC O s  to have a hydrophobic group, an electron deficient aromatic ring and 
a hydrogen bonding site (Atwal, 1992). Other common pharmacophore 
models have described the need for the Ka TpC O  to have four common 
regions. Two of these areas represent areas of lipophilic interaction and the 
other two are hydrogen bonding regions (Koga et a/., 1993). If cromakalim 
and pinacidil have common binding sites, then one would believe that the 
vasorelaxant and Rb efflux responses to these KaTpC O s  would be identical, in 
other words, they would both be either sensitive or insensitive to L-arginine 
analogues. The findings of the study show that there are similarities between 
pinacidil and cromakalim as cromakalim is insensitive to L-NAME and 
pinacidil has an L-NAME insensitive component, but the findings also show 
that pinacidil and cromakalim have a differential sensitivity to L-NAME, 
suggesting that elements of their respective binding sites are different in 
nature. The hypothesis suggesting differences in the cyanoguanidine and 
benzopyran KaTpC O  binding sites is supported in a study examining the 
cyanoguanidine KaTpC O , P1075 and the benzopyran K aTpC O , PKF217-744  
(Manley et a/., 1993: 2001). The study shows that substituents of the 
benzopyran ring of PKF217-744 make contact with SUR2B. Therefore, some 
parts of the binding site of PKF217-744 are not utilised by P1075, suggesting 
that the binding sites of the two KaTpC O s  are not identical.
7 .4  Sites of Action
The KaTp channel antagonist, glibenclamide, was shown to reduce the Rb 
efflux induced by pinacidil and cromakalim. This supports the action of 
pinacidil and cromakalim involving KAtp  channels in rat isolated aorta devoid 
of endothelium. The Na+/K+-ATPase pump inhibitor ouabain, failed to modify 
the Rb efflux produced by pinacidil or cromakalim. The failure to see a
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modification of the pinacidil or cromakalim induced Rb efflux, suggests that 
the mechanisms of action induced by pinacidil and cromakalim involve the 
K a T p  channel and do not involve the Na+/K+ATPase pump in rat isolated aorta.
The concentration response curves produced to Ka TpC O s  in the presence of 
L-arginine analogues, have been displaced to the right of the control curves 
without modifying the maximal response. This process is called surmountable 
antagonism. If all the Ka TpC O s  interacted with the KaTpC O  binding site in rat 
isolated aorta in the same manner, then it would be expected that the Hill co­
efficients would be the same. As the KaTpC O s  have been shown to interact 
with the KaTpC O  binding site in different ways, then a range of Hill co-efficient 
values have been obtained.
7 .5  Cyanoguanidine K aTpC O s
The new, thienylcyanoguanidine KaTpC O s , which are similar in structure to 
pinacidil, have played an important role in establishing the particular moieties 
of the KaTpC O  structure, which have an affinity to the K aTpC O  receptor in rat 
isolated aorta (Yoshiizumi et al., 1997). The findings of the study have shown 
that the vasorelaxant responses to pinacidil, KB-R6844, KB-R6907 and KB- 
R10757 are sensitive to L-MMA, whereas the vasorelaxant responses to KB- 
R10101 and KB-R10758 are insensitive to L-MMA (Table 7). These 
observations suggest that pinacidil, KB-R6844, KB-R6907 and KB-R10757 
activate a relaxant mechanism in rat aorta, which is independent of the 
mechanism(s) operated by KB-R10101 and KB-R10758. The findings of the 
study add further support to the hypothesis that some aspects of the KaTpC O s 
binding sites on SUR2B are different. If ail of the KaTpC O s  interact with the 
same binding site in the same way on SUR2B, then it would be expected that 
the KaTpC O s  would either all be sensitive or insensitive to L-arginine 
analogues. As the Ka TpC O s  have a differential sensitivity to the L-arginine 
analogues, then this suggests that element(s) of their binding sites are 
different.
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Compound Ri r 2 Rs Effect of L-MMA on 
Activity
Pinacidil O -C(CH3) -H Reduced
KB-R10101 -CH2.CH3 -c h 3 No Change
KB-R6844
N C \>> -CH2.CH3 -c h 3 Reduced
KB-R10757 -CH2.CH3 -c h 3 Reduced
KB-R6907
N C \
t ) -
-C(CH3)3 -H Reduced
KB-R10758 -CH2.CH3 -c h 3 No Change
Table 7. A comparison of a series of cyanoguanidines Ka TpC O s . the effect of 
L-MMA on the KatpC O s  activity is shown.
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The structural differences between the cyanoguanidine KaTpC O s  that are 
sensitive and those that are insensitive to L-arginine analogues have been 
compared. The vasorelaxant responses to KB-R6844 are sensitive to L-MMA 
whereas the vasorelaxant responses to KB-R10101 are insensitive to L-MMA. 
The only structural difference between these two compounds, is the 
substitution of a -B r group on KB-R10101 for a -C N  group on KB-R6844 at 
position Ri (Table 7). This substitution may therefore for account for the 
sensitivity of KB-R6844 to L-MMA in rat isolated aorta devoid of endothelium. 
The substitution may also result in KB-R6844 interacting with the part of the 
KaTpC O  binding site on SUR2B that is sensitive to L-arginine analogues.
The vasorelaxant responses to both KB-R10757 and KB-R6844 are sensitive 
to L-MMA in rat isolated aorta devoid of endothelium. The only structural 
difference between KB-R10757 and KB-R6844 is the positioning of the -S 
group on the thiophene ring at position Ri. The R2 and R3 groups on KB- 
R10757 are identical to those in KB-R6844. Therefore, the structural 
modification at position Ri appears not to affect the sensitivity of KB-R10757 
and KB-R6844 to L-MMA. KB-R6907 has the same Ri substitution as KB- 
R6844, and the same R2 and R3 modifications as pinacidil. Despite these 
structural differences, the vasorelaxant responses to KB-R6907 are sensitive 
to L-MMA. This suggests that the structural modifications in KB-R6907 do not 
affect the sensitivity of KB-R6907 to L-MMA.
The findings of the study suggest that the -CN group on the thiophene ring at 
position R i, is required for the thienylcyanoguanidine KaTpC O s  to show 
sensitivity to L-MMA, as the substitution of the -C N  group for a -B r group 
results in a loss of sensitivity to L-MMA.
An examination of the Ri substitutions shows that the nitrogen on pinacidil 
possesses a lone pair of electrons (i). The nitrogen is sp2 hybridized. The 
bromine on KB-R10101 also possesses a lone pair of electrons, but is more 
electronegative than the nitrogen, hence it is less willing to share the lone pair
(ii). The bromine is sp3 hybridized. However, in KB-R6844 and KB-R6907 (iii),
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the nitrogen once more possesses a lone pair of electrons, but is sp 
hybridised, which means that the electrons are held closer to the nucleus than 
in the cases of sp2 and sp3 hybridization.
Br S N =  C S
(i) Pinacidil (ii) KB-R10101 (iii) KB-R6844 & KB-R6907
In conclusion, there appears to be a requirement for a lone pair donor to be 
present at an appropriate site on the KaTpC O , to enable binding to the Ka TpC O  
receptor to occur. In addition, the atom containing the lone pair of electrons, 
has to be willing to give the lone pair up, as seen in example (i) with pinacidil. 
Despite the fact that the bromine on KB-R10101 contains a lone pair of 
electrons, it is less willing to donate the lone pair of electrons, as the bromine 
on KB-R10101 is more electronegative than the nitrogen on pinacidil.
This suggests that there is a balance between the willingness of the atom to 
donate a lone pair and the electronegativity characteristics of the group in 
question. A net effect of these two features appears to have a role in 
determining the sensitivity of the vasorelaxant responses of these Ka TpC O s  to 
L-MMA. To investigate these effects further, it would be useful to examine 
additional KaTpC O s  with similar properties. To serve this purpose, an amide 
(iv) or an amine group (v) could be substituted at position Ri. Both the amide 
and amine possess a nitrogen group, which is sp3 hybridized and is less 
electronegative than the -B r on KB-R10101. The electrons in sp3 hybridised 
atoms are held less closely to the nucleus than the electrons in sp and sp2 
hybridised atoms, hence the sp3 hybridized nitrogen group in the amide and 
amine compounds should be more willing to donate their lone pair of electrons 
than in the cases of pinacidil, KB-R6844 and KB-R6907.
91
(iv) Amide (v) Amine
The effect of L-MMA on the vasorelaxant responses to KaTpC O s  possessing 
the amide and amine groups could then be compared to the current study and 
provide additional information about the relationship between the L-arginine 
analogues, the KaTpC O s , the KaTpC O  binding site on SUR2B and the role that 
the lone pair of electrons play in this interaction.
7.6 Endothelium
In the presence of a functional endothelium, the vasorelaxant responses to 
pinacidil are sensitive to L-NAME, L-MMA and L-NNA and the vasorelaxant 
responses to KB-R6907 and KB-R6844 are sensitive to L-MMA. In addition, 
the vasorelaxant responses to KB-R6844 are also sensitive to the NOS 
inhibitor L-NIO and the guanyiate cyclase inhibitor methylene blue. In the 
absence of a functional endothelium, the vasorelaxant responses to KB- 
R6844 are insensitive to L-NIO and methylene blue. Therefore, the removal of 
a functional endothelium appears to also remove the sensitivity of the 
vasorelaxant responses to KB-R6844 to L-NIO and methylene blue in rat 
isolated aorta. In contrast, the vasorelaxant responses to pinacidil, KB-R6844 
and KB-R6907 show sensitivity to L-arginine analogues in the presence or 
absence of a functional endothelium. NOS inhibitors have previously been 
shown to modify the vasorelaxant responses to KaTpC O s , but their effects 
have been associated with endothelium-derived NO and cGMP-dependent 
pathways (Deka et al., 1998; Maczewski and Beresewicz, 1997; Lawson et 
al., 1993).
The enzyme NOS is central to the control of NO biosynthesis. There are three 
forms of NOS: an inducible form (iNOS, expressed in macrophages and
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Kupffer cells, neutrophils, fibroblasts, vascular smooth muscle and endothelial 
cells in response to pathological invasion) and two constitutive forms that are 
present under physiological conditions in endothelium (eNOS) and in neurons 
(nNOS) (Anggard, 1994).
The activity of constitutive forms of NOS is controlled by intracellular calcium- 
calmodulin. The most important stimuli controlling NO synthesis in vessels 
under physiological conditions are pulsatile flow and shear stress (Anggard, 
1994). In addition, endothelial cells possess receptors for several dilators 
including acetylcholine and substance P, occupation of which increases 
intracellular calcium and stimulates endothelial NO biosynthesis. Once NOS 
has been activated, it converts L-arginine into L-citrulline, and in the process 
produces NO. The NO then diffuses from the endothelium into the vascular 
smooth muscle where it activates the enzyme guanylate cyclase, which in turn 
converts GtP into cGMP and causes relaxation (Anggard, 1994; Nathan, 
1992).
If the sensitivity of the vasorelaxant responses of pinacidil, KB-R6844 and KB- 
R6907 to the L-arginine and L-ornithine analogues were entirely due to 
endothelial NO production, then in the absence of a functional endothelium, it 
would be expected that this sensitivity would not occur. It is possible that 
pinacidil but not cromakalim could activate NOS and in turn, the sensitivity of 
pinacidil to L-NAME could be attributed to pinacidil directly activating NOS. 
However the insensitivity of pinacidil to L-NIO supports the hypothesis that 
NOS action is not involved in the mechanisms that underpin the response of 
the rat isolated aorta devoid of endothelium to K aTpC O s . the insensitivity of 
pinacidil to L-NIO in the absence of a functional endothelium also shows that 
any NOS activity in smooth muscle is minimal. Therefore, the sensitivity of the 
Ka tpC O s  to L-arginine analogues in rat isolated aorta devoid of endothelium, 
suggests that the action of the L-arginine analogues is independent of the 
NO:L-arginine pathway.
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7.7 Future Biological Work
The findings of this study have shown that the vasorelaxant responses to 
several Ka TpC O s  are sensitive to L-arginine analogues. Binding studies could 
be used to examine whether the L-arginine analogues are having a direct 
effect on the Ka TpC O  receptor in rat vascular smooth muscle. An inhibition of 
[3H] P1075 binding by the L-arginine analogues would suggest that the L- 
arginine analogues are having a direct effect at the KaTpC O  receptor.
A demonstration that NOS was not involved in the sensitivity of Ka TpC O s  to L- 
arginine analogues would be, .useful to eliminate any effects of NO on the 
mechanism of action of KaTpC O s . Cloned KatpC O  receptors could be used to 
elucidate why certain Ka tpC O s  are sensitive to L-arginine analogues but are 
not sensitive to L-NIO and where the L-arginine analogues are having their 
effects.
The membrane currents produced by stable smooth muscle cell lines 
expressing SUR2B and Kir6.2 could be examined using the whole cell patch 
clamp technique. The current produced as a consequence of Ka tpC O  
activation could be measured in the presence of L-arginine analogues. In 
addition, the possible effects of protein kinase A and protein kinase C 
activators and inhibitors on this KatpC O  induced current could be examined.
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7 .8  Future Work -  Alternative K a tp C O s
O O
N
O
CH,
NC
CH
NH
I
O
OH
CH
Symakalim DY-9708
The vasorelaxant responses to DY-9708 but not those to symakalim are 
sensitive to L-MMA. This suggests that DY-9708 and symakalim interact with 
the KaTpC O  binding site in a different manner. At present, it is not possible to 
suggest the particular moieties of DY-9708 and symakalim, which allow this 
difference in L-MMA sensitivity to occur. To examine the difference in L-MMA 
sensitivity, it would be beneficial to synthesize some Ka TpC O s  that are similar 
in structure to both symakalim and DY-9708. Some suggestions of suitable 
compounds can be seen below.
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Compound (vii)
These two compounds fill the structural gaps between symakalim and DY- 
9708 and should provide some explanation as to the ability of L-MMA to 
modify the vasorelaxant responses to DY-9708, but not to symakalim. The 
compounds will show the parts of the KaTpC O  that are crucial in binding to the 
KaTpC O  receptor in SUR2B.
Cromakalim Bimakalim
The vasorelaxant responses to bimakalim, but not those to cromakalim are 
sensitive to L-arginine analogues. This suggests that cromakalim and 
bimakalim interact with the KaTpC O  binding site in a different manner. At 
present, it is not possible to suggest the particular moieties of cromakalim and 
bimakalim that allow this difference in L-arginine analogue sensitivity to occur.
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Two compounds have been suggested below, which may help in the 
elucidation of the L-MMA sensitivity.
Compound (viii) Compound (ix)
These two compounds may help to explain the differences in L-arginine 
analogue sensitivity seen with cromakalim and bimakalim. The compounds 
should also show which parts of the K a T p C O  are crucial in binding to the 
K a T p C O  receptor.
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8 Conclusion
The K a T p C O s  used in this study appear to fall into two categories. The 
K a T p C O s  typified by pinacidil are sensitive to L-arginine analogues whereas 
the K a T p C O s  typified by cromakalim are insensitive to L-arginine analogues. 
This sensitivity appears to be independent of NOS action as the vasorelaxant 
and Rb efflux responses to pinacidil are insensitive to the NOS inhibitor L- 
NIO. The presence of a -C N  group rather than a -B r group in 
thienylcyanoguanidine K a T p C O s  appears to be important in relation to the 
sensitivity of these K a T p C O s  to L-MMA as substituting the -C N  group for a -B r  
group removes the sensitivity for L-MMA.
A model explaining the differential vasorelaxant and Rb efflux responses to 
the K a T p C O s  has been suggested. Pinacidil and cromakalim are believed to 
have a degree of commonality in how they interact with the K a T p C O  binding 
site on SUR2B. Some parts of pinacidil though are believed to interact with 
the area of the K a T p C O  binding site that recognises L-arginine analogues 
explaining why an increased amount of pinacidil is required to produce the 
same degree of relaxation in the presence of L-arginine analogues. In 
contrast, no part of cromakalim is believed to interact with this particular 
region of the K a T p C O  binding site, which explains the insensitivity of 
cromakalim to L-NAME. In contrast to L-NAME, L-NIO is not believed to 
interact with the K a T p C O  binding site on SUR2B explaining why it is unable to 
modify the vasorelaxant responses to pinacidil.
In future, binding studies could be used to examine whether the L-arginine 
analogues are having a direct effect on the K a T p C O  receptor in rat vascular 
smooth muscle. A demonstration that NOS is not involved in the sensitivity of 
K a T p C O s  to L-arginine analogues would be useful to eliminate any effects of 
NO on the mechanism of action of K a T p C O s . Cloned K a t p C O  receptors could 
be used elucidate why certain K a t p C O s  are sensitive to L-arginine analogues 
but are not sensitive to L-NIO.
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Such information will help in the generation of agents that may play a valuable 
therapeutic role in the treatment of conditions caused by high levels of cell 
excitability.
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